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ABSTRACT 
Enterococcus faecalis is a Gram-positive commensal bacterium that resides in the human 
gastrointestinal tract. Unfortunately, E. faecalis can also cause infections in humans and 
is notoriously difficult to treat due to drug resistance. One treatment that is used to treat 
enterococcal infections is the cell membrane targeting lipopeptide antibiotic, daptomycin. 
However, daptomycin resistant strains of E. faecalis have been isolated. Studies aimed 
at understanding these resistant strains show that mutations in genes associated with 
membrane homeostasis are involved. E faecalis can also incorporate exogenous fatty 
acids from environments in which it thrives, bile (GI tract) and serum (wounds), which 
cause increased physiological tolerance to daptomycin. The host fatty acids, oleic acid 
(C18:1 cis 9) and linoleic acid (C18:2 cis 9, 12), that are prevalent in serum and bile, are 
the major factors that contribute to this induction of daptomycin tolerance. Within this 
work, I determined that the cis bond at the 9th carbon of oleic acid is critical for increased 
tolerance. Moreover, I found that when the carboxyl group of oleic acid or linoleic acid 
was replaced with an amide group, tolerance was lost. To assess if increased tolerance 
induced by these host fatty acids was a consequence of a membrane stress response, I 
examined a strain of E. faecalis which lacks the response regulator of the LiaFSR three-
component system and concluded that host fatty acid induced tolerance was not 
mediated by LiaFSR. Finally, I investigated whether or not supplementation with host fatty 
acids was altering the membrane phospholipid composition leading to increased 
tolerance. After mass spectrometry analysis, I discovered alterations in the composition 
of the major phospholipids in E. faecalis. To test these alterations, I deleted genes 
responsible for production of lysyl-phosphatidylglycerol (mprF2) and cardiolipin (cls1 and 
cls2). After supplementation with oleic acid and linoleic acid, I still observed increased 
tolerance to daptomycin. However, long term exposure to daptomycin resulted in no 
recovery even after supplementation with host fatty acids. These data suggest that oleic 
acid and linoleic acid can induce lipid alterations, but alteration in the composition of L-
PG and CL are not responsible for acute daptomycin tolerance. 
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Enterococci 
Enterococci are an ancient genus of bacteria, believed to have originated when animals 
underwent terrestrialization around 425 million years ago (1). First observed and 
characterized in 1899 (2, 3), a species of enterococci (then known as Micrococcus 
zymogenes) was isolated from a case of acute endocarditis and septicemia. The 
observations in these studies became the basis for understanding enterococci 
pathogenesis. To date, there have been over 50 species of enterococci isolated of varying 
genome sizes (from 2.3 Mb to 5.3 Mb). Enterococci are low GC, Gram-positive diplococci, 
that naturally reside in the gastrointestinal (GI) tracts of humans (comprise <0.1% of the 
total consortia) and other animals as well as insects (4–6). Further, these organisms can 
be isolated from diverse environments. The intrinsic hardiness of these organisms allows 
them to aid in the production of fermented foods and dairy products and survive in 
environmental niches such as plants, soil, and water (7). However, a more thorough 
understanding of the characteristics that allow enterococci to colonize diverse 
environments is of significant interest. In this chapter, I will specifically highlight the 
current information about enterococci physiology and processes involved in governing 
the success of this organism as a human pathogen. 
Enterococci in the clinic 
Enterococci began to emerge as a significant hospital pathogen in the 1970’s and 1980’s, 
and as demonstrated by the increased reporting of enterococci nosocomial isolates, are 
now considered a serious threat to human health (8, 9). Although enterococci naturally 
reside in the GI tract and genital tract (and to a lesser extent in the oral cavity), in an 
immunodeficient host, the bacteria can translocate the mucous membrane to cause 
systemic infection (10), colonize in-dwelling medical devices, infect surgical wounds, and 
cause endocarditis (11, 12). These infection outcomes typically arise after antibiotic 
treatment, where the intestinal microbial community is significantly altered (13–15) such 
that the density of bacterial flora is greatly reduced. However, after discontinued use of 
antibiotics, specific genera of bacteria, including enterococcus begin to increase (16). As 
a consequence of the increased numbers of these specific bacteria, enterococci can enter 
the bloodstream and cause downstream health effects. More recent epidemiological 
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investigations, however, suggests that the primary method for patient to patient spread 
occurs via the hands of healthcare workers since identical strains of enterococci have 
been found on patients and healthcare worker hands (17). This spread is attributed to the 
ability of enterococci to survive on fomites for long periods of time (18). This strategy of 
spreading bacteria becomes particularly important when dealing with nosocomial 
pathogens such as vancomycin-resistant enterococcus (VRE). If a patient carries VRE, 
other patients in the hospital are 40% more likely to be colonized by VRE (19). 
Enterococcus faecium and Enterococcus faecalis are the two most prevalent species 
of enterococcus that cause disease in a clinical setting (20). There are significant 
differences between these two species, but they share common features related to 
intrinsic antibiotic tolerance and resistance mechanisms (21). Both species are tolerant 
to b-lactam and aminoglycoside antibiotics meaning that their growth can be inhibited by 
clinical doses of these drugs, but much higher doses are required for killing. The tolerance 
mechanism to b-lactams are shared across all enterococci species examined to date and 
involve the production of low affinity penicillin binding proteins (PBPs), which prevent b-
lactams from covalently binding to PBPs thus allowing cell wall synthesis even when 
exposed to drug (22). Importantly, these species are not only broadly tolerant to the b-
lactam class of antibiotics, but specifically resistant to penicillin, ampicillin, and 
cephalosporins.  Along with high tolerance to b-lactams, the enterococci are tolerant to 
aminoglycosides due to a proposed method of exclusion (23, 24). The enterococci 
species found in the clinic can also be genetically resistant to clindamycin and 
vancomycin, and many are multi-drug resistant making treatment a challenge. 
Enterococci are also efficient at horizontally acquiring and sharing antibiotic 
resistance by using mobile genetic elements, such as conjugative transposons, 
pathogenicity islands, and plasmids (25). These mobile genetic elements can carry 
resistance genes and be shared with other clinically relevant bacterial isolates, which was 
the case for methicillin resistant Staphylococcus aureus acquiring vancomycin resistance 
from a transposon element (Tn1546) on a conjugative plasmid (26). With as much as 25% 
of the E. faecalis genome consisting of foreign DNA or mobile genetic elements, there 
are a considerable number of genes that have been discovered to promote survival in 
diverse conditions (27). Some of these genes help enterococci survive in hostile 
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conditions, such as the production of proteins for oxidative stress and cation homeostasis. 
Further, pathogenicity islands likely derived from integrated plasmids, confer the 
presence of aggregation substance (believed to be important for pathogenicity and 
conjugation (28)), cytolysin and vancomycin resistance (29).  
While horizontal gene acquisition is important for resistance to antibiotics, resistance 
to daptomycin is linked to gene mutations. Daptomycin is a calcium-dependent 
lipopeptide antibiotic used to combat multi-drug resistant enterococci. Although the action 
mechanism is still unclear, daptomycin inserts a 10-carbon fatty acid tail into the Gram-
positive membrane, in association with phosphatidylglycerol, then oligomerizes with other 
daptomycin monomers to destabilize the membrane and cause cell death (30–34). 
Despite this apparently non-specific cell membrane targeting mechanism, daptomycin 
resistant strains have been isolated in the clinic (35, 36).  
Daptomycin resistance 
Daptomycin is a cyclic lipopeptide antibiotic and natural product of the soil actinomyces, 
Streptomyces roseosporus. Isolated from Mount Ararat in Turkey in the 1980’s, 
daptomycin was first approved by the Food and Drug Administration (FDA) for clinical use 
in 2003 to treat complicated skin and soft tissue infections, infective endocarditis, and 
bacteremia associated with these diseases in Staphylococcus aureus (37, 38). Early in 
vitro experiments using the Gram-positive bacterium, S. aureus, suggested that 
resistance to daptomycin was rare and that spontaneous resistance rates were low (39). 
However, subsequent work with S. aureus demonstrated that serial passage with 
daptomycin resulted in mutations in certain genes (mprF, rpoB, yycG and others)(40) and 
that these genetic mutations could also be found in daptomycin resistant S. aureus clinical 
isolates (41, 42). 
Due to the multidrug resistance of enterococci clinical isolates, clinicians have been 
using daptomycin to treat enterococcal infections (36). In 2011, Arias et al. characterized 
a clinical pair of daptomycin-susceptible and daptomycin-resistant E. faecalis strains from 
a patient with fatal bacteremia. Deep-genome sequencing of these strains, showed the 
presence of several mutations, including lipid II interacting antibiotic component F (liaF of 
the LiaFSR three component system – discussed in more detail below), cardiolipin 
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synthase (cls – OG1RF_RS01975 “cls1”), and glycerophosphoryl diester 
phosphodiesterase (gdpD). Moreover, serial passaging of E. faecalis in the presence of 
increasing concentrations of daptomycin (in vitro evolution) demonstrated similar 
mutations to the clinical pair (35). Interestingly and not surprisingly, given the proposed 
mechanism of action of daptomycin, these mutations are in genes that encode for proteins 
involved in membrane homeostasis.  
Membrane fatty acid biosynthesis 
The cell envelope (consisting of cell wall and cell membrane) is a vital structure that allows 
bacteria to survival in a wide variety of environments. Moreover, it protects the cell from 
harmful or changing environmental conditions (temperature, pH, salinity, etc.), but allows 
the passive diffusion of important nutrients into the cell and waste products out of the cell. 
The cell membrane, in particular, is dynamic because there are many vital processes 
occurring at this region which can dictate the success of an organism. The membrane 
must change as a result of environmental alterations in order to maintain proper viscosity, 
such that passive permeability of hydrophobic molecules, active transport, and protein-
protein interactions can function appropriately (43). It has been observed that during 
changing temperatures, organisms such as Escherichia coli (44) and Bacillus subtilis (45), 
have the ability to alter the ratio of saturated (carbon tail with no double bonds) and 
unsaturated (carbon tail with at least one double bond) fatty acids to help maintain proper 
membrane flexibility and fluidity (46). E. coli can also perform post-synthetic modifications 
of unsaturated fatty acids to generate cyclopropane fatty acids, which protect the 
organism from acid shock (47). Additionally, Streptococcus mutans can increase the 
abundance of unsaturated fatty acids when it is exposed to a low pH environment, which 
in turn is linked to its ability to cause disease (48). It is clear that bacteria alter their fatty 
acid content to adjust the biophysical properties of their membranes in response to 
changing environment.  
De novo synthesis of fatty acids differs in bacteria (fatty acid biosynthesis type II – 
FAS II) as compared to eukaryotes (fatty acid biosynthesis type I – FAS I). FAS I, which 
occurs in the eukaryotic cytoplasm, employs a single multiprotein complex to complete 
fatty acid synthesis. For bacteria, however, a set of conserved genes encode individual 
6 
 
proteins for each step in fatty acid synthesis. Succinctly, in FAS II, the acyl-carrier protein 
(ACP) is responsible for carrying each fatty acid intermediate throughout fatty acid 
biosynthesis ending in a fatty acid product typically between 16 to 18 carbons in length 
(Summarized in Figure 1.1) (43, 49). First, acetyl-CoA is converted to malonyl-CoA by 
acetyl-CoA carboxylase (AccABCD). The malonyl group is then transferred to ACP by 
malonyl transacylase (FabD) to form Malonyl-ACP. Malonyl-ACP condenses with another 
acetyl-CoA by b-ketoacyl-ACP synthase III (FabH) to form b-ketoacyl-ACP. This in turn is 
reduced by b-ketoacyl-ACP reductase (FabG) to form b-hydroxy-acyl-ACP. b-hydroxy-
acyl-ACP dehydratase (FabA/FabZ or FabN in enterococcus) will then convert b-hydroxy-
acyl-ACP to trans-2-enoyl-ACP. Finally, enoyl-ACP reductase (FabI/FabK/FabL/FabV – 
isoforms depend upon the species) acts on trans-2-enoyl-ACP, thus completing the cycle 
and resulting in an acyl-ACP two carbons longer. Subsequent condensation reactions of 
2-carbon units facilitated by b-ketoacyl-ACP synthase II (FabF in enterococci and other 
species or FabB) drive the elongation of the fatty acid until the chain length reaches 16-
18 carbons. Depending on the requirement for saturated or unsaturated fatty acids 
(typically driven by temperature), the trans-2-enoyl-ACP can be isomerized to form cis-2-
decanoyl-ACP and elongated by FabF/FabO (50) (Figure 1.2). Once the fatty acid has 
been synthesized, it can be transferred to the membrane for attachment to a polar head 
group to form a glycerolipid (51, 52).  
Membrane phospholipids and incorporation of fatty acids 
The formation of phospholipids and the ability to modulate phospholipid composition is 
vitally important for cell homeostasis. The majority of bacterial species examined to date 
produce the following major phospholipids: phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), and cardiolipin (CL) (53), but can also form phosphorous-free 
membrane lipids (e.g. sulfolipids and hopanoids) (54). In Gram-positive bacteria, the 
major glycerophospholipids are typically PG and CL, but the relative abundance of these 
phospholipids is species dependent as well as growth phase and growth condition 
dependent (Reviewed in 54, 55–58). 
The most common proteins involved in the biosynthesis of membrane phospholipids 
in Gram-positive bacteria are PlsX, PlsY, and PlsC (51). After several rounds of  
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Figure 1.1. The fatty acid biosynthetic pathway and formation of phosphatidic acid.  
Acetyl-CoA carboxylase (Acc) consists of four subunits and initiates fatty acid synthesis. 
Acyl carrier protein (ACP) carries each fatty acid intermediate to the next step in the 
pathway. Fatty acid biosynthesis (Fab) enzymes are shown next to arrows which 
designate the next product in the pathway. Enzymes in red are found in Enterococcus 
faecalis.  
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Figure 1.2. Saturated or unsaturated fatty acid (FA) synthesis pathway.  
Fatty acid biosynthetic (Fab) enzymes involved in the synthesis of saturated or 
unsaturated fatty acids are next to arrows which designate the next product in fatty acid 
biosynthesis. Enzymes in red are those used by Enterococcus faecalis. 
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elongation, long chain acyl-ACP becomes a poor substrate for the elongation condensing 
enzymes of FASII, but an ideal substrate for the acyltransferase system. First, the acyl-
ACP is phosphorylated by PlsX to form acyl-PO4. The acyl-PO4 can then be used by PlsY 
to acylate the sn-1 position of glycerol-3-phosphate to form lysophosphatidic acid. 
Further, the sn-2 position can then be acylated by PlsC to form phosphatidic acid, which 
is the central precursor in the formation of membrane phospholipids. In brief, cytidine 
diphosphate-diacylglycerol (CDP-DAG) synthase (CdsA) condenses phosphatidic acid 
and cytidine triphosphate (CTP) to form CDP-DAG. CDP-DAG can then be used in two 
sequential reactions (absent in enterococcus) to first result in phosphatidylserine and then 
form phosphatidylethanolamine. Alternatively, CDP-DAG can serve as a precursor for 
phosphatidylglycerol which can then result in cardiolipin (43) (See Fig 1.3). 
An alternative mechanism involved in the biosynthesis of phospholipid precursors in 
Gram-positive bacteria relies on the incorporation of exogenous fatty acids using a series 
of fatty acid kinase (Fak) proteins (59). In this system, elucidated in S. aureus, FakB1 or 
FakB2 bind saturated or unsaturated fatty acids, respectively that are thought to have 
“flipped” into the membrane, which then allows FakA to phosphorylate the fatty acid 
bound by FakB. Depending on the length of the fatty acid, this phosphorylated fatty acid 
can then be used by the PlsX/Y/C system or undergo elongation and then incorporation. 
Phosphatidylglycerol 
One of the most abundant glycerophospholipids in Gram-positive bacterial membranes is 
the anionic lipid phosphatidylglycerol (PG). This glycerophospholipid is formed after two 
sequential reactions. First, there is a condensation reaction between glycerol-3-
phosphate (G3P) and cytidine diphosphate-diacylglycerol (CDP-DAG) which is catalyzed 
by phosphatidylglycerolphosphate synthase (PgsA) to form PG phosphate (PGP). Next, 
phosphatidylglycerol phosphate phosphatase (PgpP) dephosphorylates PGP to form PG. 
Overall, PG contains two acyl chains that are esterified to a glycerol that is then bound 
to a headgroup, which gives this phospholipid a net negative charge. PG has a variety of 
functions in the membrane depending on the bacteria in question, but it has been 
demonstrated via X-ray crystallography to bind transmembrane proteins and is thought 
to help stabilize those proteins (e.g. cytochrome c oxidase) (60, 61). Moreover, the  
10 
 
 
 
 
 
 
 
 
 
Figure 1.3. Phospholipid synthesis pathway in bacteria. 
Phosphatidic acid produced from fatty acid synthesis is converted to cytosine diphosphate 
(CDP)- diacylglycerol (DAG) and is the central precursor. Phosphatidylethanolamine is a 
major phospholipid in most bacteria and is produced in two steps. Phosphatidylglycerol 
is another major phospholipid and also produced in two steps. Lysinylation of 
phosphatidylglycerol produces lysyl-phosphatidylglycerol. Cardiolipin is produced using 
several methods 1) condensation of two phosphatidylglycerol, 2) CDP-DAG and 
phosphatidylglycerol, 3) phosphatidylethanolamine and phosphatidylglycerol. 
Enterococcus faecalis lacks the enzymes to make phosphatidylserine and 
phosphatidylethanolamine. 
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headgroup of PG can be modified by the transfer of an amino acid, such as alanine, 
arginine, and lysine (62). Aminoacylation of PG in the membrane of bacteria is a 
mechanism that species of bacteria employ to repel positively charged antimicrobial 
peptides (e.g. cationic antimicrobial peptides) (63). Further, one particular aminoacylation 
that has been implicated in daptomycin resistance is lysyl-phosphatidylglycerol (64). 
Lysyl-phosphatidylglycerol 
Aminoacylated phosphatidylglycerols are commonly found in Gram-positive cytoplasmic 
membranes. The addition of lysine to PG is one way that bacteria can modulate the 
charge of the membrane, shifting PG from a net negative to a net positive charge. The 
process by which lysine is added to PG is facilitated by multiple peptide resistance factor 
F (MprF) which has been shown to transfer lysine from Lys-tRNALys to the distal hydroxyl 
group of the glycerol on PG (65). Further, it is believed that MprF synthesizes L-PG in the 
inner leaflet and that the N-terminal hydrophobic domain of MprF can transfer L-PG from 
the inner leaflet to the outer leaflet (66). Studies have shown a clear link between 
increasing lysyl-PG and resistance to killing by antimicrobial peptides (67) and other 
cationic peptides such as daptomycin in S. aureus. 
 MprF has been found in several Gram-positive bacteria. In E. faecalis, there are two 
putative mprF genes (mprF1 – OG1RF_RS00150 and mprF2 – OG1RF_RS03930) (68). 
Conversely, in S. aureus (69) and Listeria monocytogenes (70) there is only one mprF 
gene. To assess the function of mprF1 and mprF2 in E. faecalis, each gene was deleted 
and under the growth conditions examined, it was shown that loss of mprF2 abolished 
lysyl-PG production, while loss of mprF1 was no different from the parental strain. Further, 
resistance to cationic antimicrobial peptides was attributed to mprF2 (68). 
Cardiolipin 
Cardiolipin is a an anionic (carrying two negative charges) glycerophospholipid that 
makes up a portion of the bacterial cell membrane. This glycerophospholipid is unusual 
from the other lipids discussed above due to the presence of two diacylphosphatidyl 
molecules linked by a central glycerol group. As a consequence, the presence of a small 
head group relative to the hydrophobic tails, gives this lipid a peculiar and vital function 
12 
 
for cellular processes, such as the stabilization of membrane proteins and formation of 
membrane domains. Specifically, cardiolipin can act as a flexible linker that fills gaps at 
protein interfaces resulting in the stabilization of individual subunits of oligomeric proteins 
(71). Moreover, given the propensity for this lipid to form domains in the membrane, it can 
act as a proton trap when in proximity to oxidative phosphorylation complexes (72) and 
other respiratory complexes (73). Additionally, given its shape, domains of cardiolipin can 
form at regions of higher curvature and aid in bacterial division (74). 
Cardiolipin domains in several model organisms have been shown to reside at the 
cell septa and cell poles (75). It is thought that the intrinsic-curvature (small head group 
relative to large hydrophobic tails) promotes the self-organization of this lipid to these 
regions (76). Additionally, in Bacillus subtilis it was observed that the phospholipid 
synthase responsible for generating cardiolipin was found primarily at the septa (77). 
Interestingly, the number of genes responsible for cardiolipin synthesis varies by bacterial 
species, and the expression of these genes appears to correlate with physiological state 
(increase when approaching stationary phase, nutrient depravation or osmotic stress 
(78)).  
Cardiolipin is synthesized by bacteria using three currently known mechanisms: 1) 
the condensation of two PG molecules via a phospholipase D superfamily type cardiolipin 
synthase (PLD – Cls most commonly found throughout Gram-positive and -negative 
bacteria), 2) the condensation of CDP-DAG and PG via CDP alcohol 
phosphatidyltransferase type cardiolipin synthase (CAP-Cls discovered in Streptomyces 
coelicolor and most Actinobacter (79)), and 3) the condensation of PG and 
phosphatidylethanolamine (PE) via PLD-Cls (discovered in E. coli (80)). Interestingly, the 
number of cardiolipin synthase genes depends on the bacterial species and the reason 
for this is not known. In E. faecalis, there are two predicted cardiolipin synthase (cls) 
genes, similar to S. aureus (81). Alternatively, B. subtilis (82) and E. coli (80) have three 
cardiolipin synthase genes. Despite the number of cls genes in each organism, there does 
appear to be specific regulation of the genes such that they are expressed at relevant 
times. This mechanism was particularly important in S. aureus and the organism’s ability 
to respond to osmotic stress (55). In these data it was found that cls2 was a housekeeping 
gene and that cls1 responded to high-salt concentration. 
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Cell envelope function and stress response 
An ability to respond efficiently to environmental changes or niche competition is a key 
requirement for bacterial cell survival. This requires sensitive and constant monitoring of 
the environment, such that an appropriate response can be initiated and achieved. The 
interface between the environment and the inner cell is known as the cell envelope. For 
most bacterial species, immediately outside of the cytoplasmic membrane is a layer of 
peptidoglycan, consisting of sugar chains crosslinked with peptide bridges, which make 
up a flexible yet strong cell wall. In Gram-positive bacteria, this layer tends to be thicker 
on average and is exposed directly to the environment. Conversely, in Gram-negative 
bacteria, this layer is often thinner and is located between an inner and outer membrane. 
The peptidoglycan layer is an active region as it must undergo biosynthesis, assembly, 
maturation, disassembly, and recycling to allow for the maintenance of cell shape and 
cell division (83). Overall, the cell wall portion of the cell envelope provides protection 
from the environment and also offsets the turgor pressure from within the cell. However, 
many of the stress response elements that a cell uses to respond to environmental 
changes are found at the cell membrane where lipid modifications and the embedded 
proteins play a specialized role in responding to environmental cues. 
Modifying the composition of the cell membrane (as outlined above) is critical for 
survival during environmental stress. Beyond the architecture of the lipid constituents, the 
regulatory mechanisms controlling stress responses are vast. In short, there are 
numerous two or three component systems (TCS) and extracytoplasmic function (ECF) 
sigma factors that can be induced in the presence of environmental stresses. In Gram-
positive bacteria, these two systems are functionally similar because they each contain a 
membrane-anchored sensor (histidine kinase or anti-sigma factor, respectively) and a 
cytoplasmic transcriptional regulator (response regulator or ECF sigma factor, 
respectively) (84). Under homeostatic conditions, these two stress response mechanisms 
are similar in that the transcriptional regulator is kept inactive until the regulator is turned 
on by stress and subsequently involved in inducing gene expression. However, the 
mechanisms by which the membrane sensor and the regulator interact with each other is 
different. 
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In a TCS, there is a transfer of a phosphoryl group from the transmembrane sensor 
to the response regulator. This response regulator can then act on its cognate genetic 
sequence to induce a transcriptional response to mitigate damage caused by the stress. 
Alternatively, the ECF sigma factor is normally bound to the anti-sigma factor. Upon stress 
stimulation, the anti-sigma factor is released either by conformational change or by anti-
sigma factor proteolysis. The free sigma factor can then recruit RNA polymerase to initiate 
transcription at the designated promoter to result in transcription of the appropriate stress 
response genes.  
A particularly important three component system associated with cell envelope stress 
responses is the LiaFSR (lipid II cycle interfering antibiotic sensor and response regulator) 
system. In this well conserved system found across the Firmicutes group, LiaS is the 
transmembrane sensor histidine kinase, LiaR is the cytoplasmic response regulator, and 
LiaF acts as a strong inhibitor of LiaR-dependent activity (85). Work using Bacillus subtilis 
has shown that LiaSR responds to cell wall antibiotics, such as vancomycin, bacitracin, 
and other cationic antimicrobial peptides as well as cell membrane targeting antibiotics 
like daptomycin (86, 87). Moreover, the orchestrated activity of this three-component 
system in Streptococcus mutans showed transcription induction of membrane protein 
synthesis, peptidoglycan biosynthesis, and other systems involved in cell envelope 
homeostasis (88). In enterococci, a single amino acid deletion in LiaF results in 
daptomycin resistance (89–91). Conversely, the loss of LiaR results in daptomycin 
hypersusceptibility in enterococcal species (92, 93). 
Fatty acid supplementation provides protection against the 
membrane stressors, sodium dodecyl sulfate and daptomycin 
Bacteria within a host have access to a rich milieu of fatty acids from complex sources, 
like bile (gastrointestinal tract) and serum (wounds). Further, some bacteria will 
incorporate these fatty acids from host fluids (94, 95). Yet, the mechanism of how 
exogenous fatty acids are brought into bacterial cells is not completely understood. in 
Gram-negative bacteria, there is a transport mechanism which relies on FadL to facilitate 
entry of long chain fatty acids into the periplasmic space and then FadD to bring the fatty 
acid through the inner membrane where it can be acted upon by downstream enzymes 
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(96, 97). Gram-positive bacteria, on the other hand, do not have a known transport system 
for fatty acids and it is thought that these bacteria can act upon exogenous fatty acids 
after they have flipped into the lipid bilayer using a pH gradient (59). Despite the 
uncertainty of the fatty acid uptake mechanism in Gram-positive bacteria, accessing the 
fatty acids in bile and sera does occur for a variety of species (94, 95). 
We have published data showing that E. faecalis can take in and incorporate 
exogenous fatty acids. Moreover, incorporating exogenous fatty acids can impact 
physiology, but the effect a supplied fatty acid can have on the cell appears to be 
dependent on the type of fatty acid provided. In general, supplementing E. faecalis with 
either saturated fatty acids or unsaturated fatty acids results in a membrane dominated 
by the supplemented fatty acid, displacing a membrane composition which has a 
saturated:unsaturated fatty acid ratio of 1 (98, 99). Interestingly, E. faecalis incorporates 
exogenous fatty acids at the detriment of its physiology because supplementing with 
specific, individual fatty acids can have disparate effects on generation time as well as 
cell morphology (99). Saturated fatty acids (C12:0-C20:0) tend to result in improper division, 
except for arachidic acid (C20:0). Further, unsaturated fatty acids can result in more 
rounded cellular morphology (particularly palmitoleic acid – C16:1cis9). Surprisingly, 
supplementation with specific fatty acids can impact sensitivity to membrane damaging 
agents. 
When E. faecalis is grown in the presence of bile or serum, the composition of the 
membrane is altered with different native fatty acids as well as host specific fatty acids 
(98). Exposing bile or serum supplemented E. faecalis to membrane damaging agents 
like sodium dodecyl sulfate (SDS) or daptomycin, resulted in increased cell survival as 
compared to controls. When individual fatty acids were supplemented (as determined by 
those fatty acids that appeared after bile or serum supplementation), only the host 
associated unsaturated fatty acids, oleic acid and linoleic acid, improved tolerance to both 
SDS and daptomycin. Conversely, native unsaturated fatty acids, like cis-vaccenic acid, 
or native saturated fatty acids, like stearic acid, did not increase tolerance to SDS or 
daptomycin. 
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Summary 
In the following dissertation work, I have investigated how host fatty acids increase 
tolerance to membrane stressors in the Gram-positive bacterium, E. faecalis. This work 
began by following the observation that supplementing E. faecalis with the host fluids, bile 
and serum, provided specific exogenous fatty acids that could improve survivability 
(protective) to sodium dodecyl sulfate, high bile, and the antibiotic daptomycin. However, 
the mechanism for how host fatty acids increase tolerance to membrane stressors 
remained unknown. In the subsequent chapters of this dissertation, I present work 
performed to address this question. In chapter 2, I examined the properties of the 
protective fatty acids, linoleic acid and oleic acid that induce membrane stress tolerance. 
In chapter 3, I addressed whether induction of daptomycin tolerance by fatty acids is 
dependent upon the LiaFSR three component system. In chapter 4, I assessed the role 
of specific phospholipid alterations in daptomycin tolerance. Finally, in chapter 5, I discuss 
the implications of my findings in regard to E. faecalis, daptomycin tolerance, and 
membrane stress responses for future work. 
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Abstract 
Enterococcus faecalis is a commensal bacterium and hospital acquired pathogen that is 
resistant to many antibiotics. Daptomycin is a lipopeptide antibiotic that is currently being 
used to treat drug resistant enterococcal infections. Previous data has shown that 
supplementation with host fluids can increase tolerance to daptomycin. Further 
experimentation with host fluid constituents showed that oleic acid and linoleic acid 
increased tolerance to daptomycin. In this study, we test certain properties of oleic acid 
and linoleic acid and show that analogs of these protective fatty acids can impact the 
induction of daptomycin tolerance. We found that changing the double bond in oleic acid 
from cis to trans (elaidic acid), resulted in a loss of daptomycin tolerance. Further, fatty 
acid analogs containing an amide-group could be found in the membrane after 
supplementation but could not increase daptomycin tolerance. These results indicate that 
bond orientation and the carboxyl-group are important for host fatty acid induced 
daptomycin tolerance. 
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Introduction 
Enterococcus faecalis is a Gram-positive commensal bacterium capable of causing 
clinical complications in immunocompromised individuals (1). Unfortunately, this 
organism is inherently resistant to many therapeutics leaving few options for treatment. 
One treatment used by clinicians to eliminate drug resistant enterococci is the membrane 
targeting antibiotic daptomycin. Daptomycin is a lipopeptide antibiotic that associates with 
phosphatidylglycerol, oligomerizes with other daptomycin monomers to destabilize the 
membrane and causes cell death (2–5). Despite initial evidence that daptomycin 
resistance was rare in clinical trials (6), resistant strains have been isolated from the clinic 
and studied (7). Moreover, in vitro evolution experiments also showed a capacity for 
enterococci to develop resistance to daptomycin (8). Genetic analysis of daptomycin 
resistant clinical isolate and an in vitro evolved strain showed that genes responsible for 
cell membrane homeostasis were contributing (9, 10).  
Genetic alterations are not the only mechanism for increasing daptomycin tolerance. 
When E. faecalis is grown in the presence of bile or serum, E. faecalis can incorporate 
fatty acids from these sources resulting in increased daptomycin tolerance (11, 12). It is 
thought that exogenous fatty acids flip into the Gram-positive membrane using a passive 
proton mediated process. Work in Staphylococcus aureus showed that fatty acid binding 
protein B (FakB) binds to the fatty acid, which subsequently allows fatty acid kinase 
(FakA) to phosphorylate the exogenous fatty acid (13, 14). After phosphorylation, the 
activated fatty acid can be used in phospholipid synthesis. E. faecalis incorporation of 
exogenous fatty acids is believed to occur in a similar fashion (13). 
Not surprisingly, incorporation of exogenously supplied fatty acids into the membrane 
of E. faecalis leads to an altered membrane phospholipid composition (unpublished 
observations) and physiological changes, dependent upon the fatty acid provided (12). 
We have also shown that supplementation of an individual fatty acid to E. faecalis can 
impact generation time and dramatically alter cellular morphology (12). Further, we 
observed that supplementation with both host fatty acids, oleic acid (C18:1 cis-9)  or linoleic 
acid (C18:2 cis-9,12), contributed to increased daptomycin tolerance but addition of either 
saturated fatty acids or cis-vaccenic acid (C18:1 cis-11 – unsaturated fatty acid produced by 
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E. faecalis), did not increase daptomycin tolerance (12). These data implied that specific 
properties of oleic acid and linoleic acid are contributing to daptomycin tolerance.  
In the present study, we use analogs of oleic acid and linoleic acid (Supplemental 
Table 2.1) to determine which specific properties of these fatty acids induce daptomycin 
tolerance. We found that bond orientation is important, that increasing the degree of 
unsaturation does not increase tolerance, and that the carboxyl group in oleic acid and 
linoleic acid is critical for fatty acid mediated daptomycin tolerance. 
Materials and Methods 
Bacterial growth conditions. E. faecalis OG1RF was grown statically in brain heart 
infusion medium (BHI; BD Difco) at 37°C. To examine the effects of fatty acids and 
indicated analogs on growth, overnight cultures were diluted into fresh BHI medium 
containing fatty acid supplement to an optical density at 600 nm (OD600) of 0.01 and 
allowed to grow until stationary phase. For short-term supplementation experiments, 
overnight cultures were diluted into fresh BHI medium as described above and grown 
until an OD600 of ~0.25. Fatty acid supplements or analogs were then added at 
concentrations indicated in the text and incubated at 37°C for 30 minutes (12). All fatty 
acids and chemicals were purchased from Sigma-Aldrich unless noted otherwise. 
GC-FAME preparation and analysis. Cells were grown to log phase using the short-
term supplementation strategy as described above. After exposure to exogenous fatty 
acids or analogs, 15 mL aliquots of cells were washed twice with 10 mL of 1X phosphate 
buffered saline (PBS), pelleted, and stored at -80°C prior to shipment to Microbial ID, Inc. 
(Newark, DE). Cells were then subjected to saponification with a sodium hydroxide-
methanol mixture, a methylation step, and hexane extraction prior to GC-FAME analysis 
(15). 
Membrane challenge assays. Cells were grown in BHI medium until exponential phase 
(OD600 of ~ 0.25) and supplemented with either ethanol (final concentration of 0.1%) or 
dimethyl sulfoxide (DMSO; final concentration of 0.2%) as solvent controls, 20 µg mL-1 
oleic acid (C18:1 cis-9), 20 µg mL-1 elaidic acid (C18:1 trans-9), 20 µg mL-1 oleamide (C18:1 cis-9 
with amide group), 20 µg mL-1 oleyl sulfate (C18:1 cis-9 with sulfate group), 10 µg mL-1 linoleic 
acid (C18:2 cis-9, 12), 10 µg mL-1 linoleamide (C18:1 cis-9,12 with amide group), or 10 µg mL-1 
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linolenic acid (C18:3 cis-9, 12, 15) for 30 minutes (12). 10 mL of cells were harvested, washed 
twice with 10 mL of 1X PBS, then resuspended in BHI containing 1.5mM CaCl2 and 
treated with 15 µg mL-1 of daptomycin. Serial dilutions were plated onto BHI agar at 0, 15, 
30, and 60 minutes after exposure to daptomycin. The log ratio of survivors over time was 
calculated for three biological replicates and shown are the averages and standard 
deviations for each experiment. 
Phospholipid Extraction for Mass Spectrometry. Cells that received short-term fatty 
acid supplementation were washed twice with 1X PBS and then resuspended in 1 mL of 
1X PBS containing 100µg mL-1 of lysozyme. Cells were incubated at 37°C for 20 minutes 
and then transferred to a plastic screw top microfuge tube containing 0.5g of ≤106µm 
glass beads. Cells were subsequently homogenized using a mini-bead beater (Biospec 
Products, Bartlesville, OK) for two, one-minute intervals. Using a modification to the Folch 
et al. (16) and Bligh and Dyer (17) methods, homogenized cells were transferred from the 
microfuge tube to a 15 mL polypropylene conical containing 2:1 (v/v) 
chloroform:methanol. After vortexing gently, the conical tubes were centrifuged for 5 
minutes at 2739xG. The organic and inorganic phases were collected, leaving behind any 
debris and transferred to a new 15mL polypropylene conical containing 1.5 mL of 0.9% 
NaCl. After vortexing gently, the conical tubes were centrifuged for 5 minutes at 2739xG. 
Finally, the lower organic phase, containing extracted lipids, was collected and transferred 
to a glass screw top and evaporated with nitrogen gas. 
Ultra-performance liquid chromatography-high resolution mass spectrometry. An 
untargeted lipid analysis was performed on cells supplemented with the above- 
mentioned fatty acids using a Dionex UPLC (Thermo Scientific, Waltham, MA) and an 
Exactive Plus Orbitrap mass spectrometer (Thermo Scientific, Waltham, MA) in the 
method of Tague et al (submitted). Briefly, separation was preformed using a HILC 
column allowing for separation based on the head group’s interaction with the stationary 
phase. Both mobile phases consisted of 10 mM ammonium formate adjusted to pH 3.0. 
Mobile phase A was 100% water, and mobile phase B was 97:3 acetonitrile: water. A 
gradient from 0% A to 52% A was used over 25 minutes followed by 10 minutes of re-
equilibration. The elutant was analyzed using electrospray ionization and data was 
collected in negative and positive mode with a scan range from 100-1500 m/z.  All ion 
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fragmentation at 35 eV was used as a qualitative confirmation of lipid fragments. 
Phospholipid standards (Avanti Polar Lipids, Inc. Alabaster, AL), were run to verify 
retention time (RT) and gain exact m/z for each lipid class. The phosphatidylglycerol 
standard had two octadecanoic acid tails (PG 36:0), and the lysyl-phosphatidylglycerol 
standard had two oleic acids tails (L-PG 36:2). All other lipids within each head group 
have the same ionization efficiency and RT as the corresponding standard so an exact 
standard for each individual phospholipid detected was not necessary.  
Full Scan .raw files generated by the mass spectrometer were converted to .mzML 
files by MS convert (18, 19). MAVEN software (20) was used to integrate areas under the 
curve for all compounds detected based on a mass window of ± 5 ppm, exact m/z and 
known RT. Heat map visualizations were created in R using an in house created script by 
averaging values for each treatment and comparing them to the appropriate controls. 
Ratios were then log2 transformed and assigned a color based on degree of change. An 
orange color indicates the specific lipid is more abundant in the fatty acid supplemented 
cells compared to the control. A blue color represents the lipid detected is less abundant 
compared to the control. Five biological replicates for each supplement were analyzed 
and significance was determined using a two-tailed unpaired Student’s t-test. 
Statistical analysis. Differences in the membrane phospholipid or fatty acid content 
between growth conditions as well as differences in log ratio of survivors over time were 
determined using a two-tailed, unpaired Student’s t test. 
Results 
Appropriate bond orientation of unsaturated fatty acids is required for the 
induction of daptomycin tolerance. We previously showed that growing E. faecalis 
OG1RF in the presence of specific host fatty acids (oleic acid and linoleic acid) increased 
tolerance to the antibiotic daptomycin (11, 12). However, the reason why these specific 
fatty acids, and not cis-vaccenic acid, stearic acid, or palmitic acid, increased daptomycin 
tolerance had yet to be elucidated. To better determine the unique properties of oleic acid 
and linoleic acid that induced protection, we used a series of oleic acid and linoleic acid 
analogs.  
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As both oleic acid and linoleic acid are 18-carbon containing unsaturated fatty acids 
with cis bonds, we were interested to determine if bond orientation (cis versus trans) was 
critical to our observations. Previous data showed that supplementing E. faecalis OG1RF 
with oleic acid (C18:1cis-9) does not impact generation time as compared to solvent controls 
(11, 12) and similarly, elaidic acid (C18:1trans-9), did not impact generation time (Table 2.1). 
To conclude if elaidic acid was present in the membrane of OG1RF, we conducted gas 
chromatography of fatty acid methyl esters (GC-FAME) (see Materials and Methods). As 
seen in Table 2.2, elaidic acid was abundantly present, with 67% of the membrane fatty 
acid composition containing this fatty acid. As a consequence, the percent totals of all 
other fatty acids, including palmitic acid and cis-vaccenic acid were reduced.  
Both growth analysis and membrane analysis of fatty acids indicated that 
supplementation with elaidic acid (C18:1 trans 9) was similar to oleic acid (C18:1 cis 9) (11, 12). 
To assess whether or not a cis bond at the 9th position of a C18 acyl tail was critical for 
daptomycin tolerance, we supplemented OG1RF with oleic acid or elaidic acid. As shown 
in Figure 2.1, supplementation with elaidic acid did not induce daptomycin tolerance and 
was similar to the solvent control. Thus, changing the cis bond at the 9th position (oleic 
acid) to a trans bond at the 9th position (elaidic acid) does not induce daptomycin 
tolerance. These data suggest that the cis bond is critical for stress survival against 
daptomycin.  
 
Supplementation with linolenic acid impacts growth kinetics, does not increase 
daptomycin tolerance. Our previous findings indicated that linoleic acid (C18:2 cis 9, 12, two 
double bonds) may induce better protection from daptomycin than oleic acid (C18:1 cis 9, 
one double bond) (11).  These data made us question if increasing the number of cis 
bonds could further promote fatty acid induced tolerance. First, we tested how E. faecalis 
responded to supplementation with linolenic acid (C18:3 cis 9,12,15). We found that the 
generation time of OG1RF with linolenic acid was statistically greater than solvent control 
(Table 2.1), but similar to linoleic acid (C18:2cis-9,12) (11). Surprisingly, short-term 
supplementation with linolenic acid was not detected in the membrane when using GC-
FAME analysis (see Discussion). However, this is likely due to insufficient detection 
sensitivity during analysis.  
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Table 2.1. Generation times for E. faecalis OG1RF 
after supplementation. 
Supplementa Concentration Generation time (min) 
Ethanol 0.1% final 36.9 ± 0.3 
DMSO 0.2% final 37.0 ± 0.7 
Oleic acid 20 µg mL-1 47.0 ± 1.1 
Elaidic acid 20 µg mL-1 48.9 ± 0.8 
Oleamide 20 µg mL-1 40.0 ± 1.6 
Oleyl sulfate 20 µg mL-1 37.9 ± 0.2 
Linoleic acid 10 µg mL-1 88.2 ± 8.3 
Linolenic acid 10 µg mL-1 78.2 ± 5.0 
Linoleamide 10 µg mL-1 850.1 ± 190 
 
aBHI medium was used for all cultures. 
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Table 2.2. E. faecalis OG1RF membrane fatty acid composition after short-term supplementation 
with host fatty acid analogs. 
 
aMembrane content was determined using GC-FAME analysis by Microbial ID, Inc.; 
numbers represent average ± standard deviation from three independent cultures. ND 
indicates that fatty acid was not detected. 
bOther indicates fatty acids that comprised <1% of the total membrane content. 
cFatty acid length ratio includes both saturated and unsaturated fatty acid. 
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Figure 2.1. Short-term fatty acid supplementation with elaidic acid (C18:1 trans 9) fails 
to protect E. faecalis OG1RF from daptomycin challenge.  
OG1RF was grown to mid log phase and then the culture was split and supplemented 
(see Materials and Methods). Oleic acid supplementation of OG1RF increased the 
number of survivors versus the solvent control at all time points (P = 0.008) while elaidic 
acid did not. Shown are the average ± standard deviation for n = 3. 
 
 
 
 
 
 
 
0 15 30 45 60
-5
-4
-3
-2
-1
0
Time (minutes)
Lo
gN
/N
0
OG1RF + Ethanol
OG1RF + Oleic acid
OG1RF + Elaidic acid
* * *
38 
 
Given the impact on growth, we examined whether short-term supplementation with 
the fatty acid could induce daptomycin tolerance in OG1RF. As shown In Figure 2.2, 
linolenic acid did not induce tolerance. Thus, simply increasing the number of cis bonds 
in a fatty acid is not sufficient to alter sensitivity to daptomycin. 
 
Supplementation with fatty acids containing an amide group did not increase 
daptomycin tolerance. Studies have shown that the phosphorylation of exogenous fatty 
acids is important for incorporation into phospholipid synthesis (13). Further, fatty acids 
lacking a carboxyl-group cannot be phosphorylated by the fatty acid kinase system (21). 
To test if the carboxyl-group of linoleic acid and oleic acid is required for host fatty acid 
induced daptomycin tolerance, we tested several fatty acids which harbor an amide-group 
(oleamide or linoleamide) or a sulfate-group (oleyl sulfate) instead of a carboxyl-group.  
Supplementing OG1RF with fatty acids lacking a carboxyl-group had variable effects 
on generation time (Table 2.1). Oleamide (C18:1cis-9 with amide group) and oleyl sulfate 
(C18:1cis-9 with sulfate group) had no impact on generation time. Conversely, the generation 
time after linoleamide (C18:2cis-9,12 with an amide group) supplementation was ~22 times 
longer than the solvent control and ~10 times longer than linoleic acid. These alterations 
(or lack thereof) in generation times, however, were not necessarily reflective of their 
presence in the membrane via GC-FAME. After short-term supplementation with 
oleamide and linoleamide, we found that about 35% and 30% (reported as C18:1 cis 9 or 
C18:2 cis 9,12 respectively) of the membrane contained these fatty acids. However, oleyl 
sulfate was not detected via GC-FAME because this fatty acid cannot be esterified due 
to the lack of carbonyl moiety. Interestingly, after oleyl sulfate supplementation we did 
notice the presence of unique fatty acids, such as cetyl alcohol (C16 N alcohol) and 
heptadecenoic acid (C17:1 cis 10).  
To test if fatty acid incorporation onto phospholipid head groups is necessary for 
increased daptomycin tolerance, we challenged cells supplemented with oleamide, 
linoleamide, or oleyl sulfate against daptomycin (Figure 2.3). As seen in Figure 2.3A, 
supplementation with oleamide did not increase tolerance to daptomycin and is similar to 
the dimethyl sulfoxide (DMSO) solvent control. Similarly, linoleamide (Figure 2.3B) did 
not increase tolerance to daptomycin. Surprisingly, supplementation with oleyl sulfate  
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Figure 2.2. Short-term fatty acid supplementation with linolenic acid fails to protect 
E. faecalis OG1RF from daptomycin challenge.  
OG1RF was grown to mid log phase and then the culture was split and supplemented 
(see Materials and Methods). Linoleic acid supplementation of OG1RF increased the 
number of survivors versus the solvent control at all time points (P = 0.0004) while 
linolenic acid supplementation of OG1RF did not. Shown are the average ± standard 
deviation for n = 3. 
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Figure 2.3. Short-term supplementation with fatty acids without a carboxyl group 
do not protect OG1RF from daptomycin challenge. 
OG1RF was grown to mid log phase and then the culture was split and supplemented 
(see Materials and Methods). (A) Oleic acid supplementation of OG1RF increased the 
number of survivors versus the ethanol solvent control at all time points (P = 0.008) as 
did oleyl sulfate (P = 0.0024). Oleamide supplementation did not increase the number of 
survivors versus the DMSO solvent control. (B) Linoleic acid supplementation of OG1RF 
increased the number of survivors versus the ethanol solvent control at all time points (P 
= 0.0004) while linoleamide did not. Shown are the average ± standard deviation for n =3. 
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significantly increased (P ≤ 0.0024) tolerance to daptomycin as compared to the ethanol 
control. 
Taken together, short-term supplementation with fatty acids that lack a carboxyl-
group are found in the membrane as determined by GC-FAME. Further, it appears that 
the carboxyl-group is important for increased tolerance to daptomycin. However, oleyl 
sulfate appears to be inducing a mechanism of tolerance, possibly unrelated to our 
previous observations (see Discussion). 
 
Fatty acid analogs can be found free in the membrane. We observed that ~30% of 
the membrane fatty acid composition contained oleamide and linoleamide after short-
term supplementation (Table 2.2). These data were surprising, since previous studies 
suggested that a fatty acid without a carboxyl group should not be phosphorylated by 
FakA (21), which is needed for incorporating exogenous fatty acids into phospholipid 
synthesis (13). Given that we observed the presence of oleamide and linoleamide in the 
GC-FAME results, we wanted to confirm whether these fatty acids were associated with 
phospholipid head groups, free within the membrane, or both. To discern these 
possibilities, we used an untargeted mass spectrometry method (see Materials and 
Methods). Collectively, our analysis detected 19 phosphatidylglycerol (PG) species, 18 
lysyl-phosphatidylglycerol (L-PG) species, and the presence of each of the supplemented 
fatty acids (oleic acid, elaidic acid, linoleic acid, linolenic acid, oleamide, linoleamide, and 
oleyl sulfate) in our cell extract samples. 
When cells were given oleic acid, the amount of oleic acid as a free fatty acid in the 
membrane was significantly higher than the solvent control (66 – fold increase) (Figure 
2.4). As a whole, all detected L-PG species were increased over the solvent control. 
Conversely, most PG species were decreased (exception PG 38:1). Similarly, when cells 
were supplemented with linoleic acid, there was an increase in free linoleic acid (92,000 
– fold), along with an increase in all L-PG species; with major increases in L-PG which 
could contain linoleic acid tails (34:3, 34:4, 36:3, 36:4). These data show that host fatty 
acids can be found free in the membrane as well as in membrane phospholipids, such as 
L-PG.  
To test if changing the cis bond to a trans bond on a C18 acyl tail impacted localization 
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Figure 2.4. Untargeted mass spectrometry of phospholipids and free fatty acids 
after supplementation of E. faecalis OG1RF with host fatty acids and their analogs.  
Columns represent the supplement and rows represent the species detected (Top) 
phospholipids and (Bottom) free fatty acids. 20 µg mL-1 of oleic acid analogs (elaidic acid, 
oleyl sulfate, and oleamide) and 10 µg mL-1 of linoleic acid analogs (linolenic acid and 
linoleamide) were supplemented to n = 5 biological replicates. Shown is a heatmap of fold 
changes relative to solvent controls. 
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of the fatty acid, we supplemented OG1RF with elaidic acid and analyzed the cell 
membrane extract. We found that elaidic acid was free in the membrane (39.8 –fold) and 
was also likely incorporated onto several phospholipid species (L-PG 36:2 and PG 36:2). 
Upon supplementation with oleamide, a large amount of the fatty acid was found free 
in the membrane (99.3 – fold). Interestingly, we found minimal phospholipid incorporation 
of the fatty acid. It appeared that only L-PG 32:0, 34:4, and 36:4 were increased, and 
unlikely the result of oleamide incorporation. 
Similarly, supplementation with linoleamide resulted in a higher abundance of free 
linoleamide in the membrane (103.8 – fold) as compared to the solvent control. 
Interestingly, there was an increase in several L-PG species such as L-PG 34:2, 34:3, 
34:4 (highest fold change), 36:3, and 36:4, which is a result of linoleamide 
supplementation, but likely not direct phospholipid incorporation. There were also 
significantly lower levels of most detected PG classes after linoleamide addition, a 
reaction similar to supplementation with linoleic acid. 
Unlike oleamide and linoleamide, oleyl sulfate possesses a sulfate instead of a 
carboxyl group. The lipid profile for this treatment resulted in large decreases in all L-PG 
and PG. Unlike GC-FAME, it was possible to measure free oleyl sulfate and there was a 
large increase in the relative amounts detected in the membrane (28,334 – fold). Despite 
the increased presence of this fatty acid free in the membrane, it did not appear to be 
present in the phospholipid profile. 
Discussion 
Supplementation of E. faecalis OG1RF with the host fatty acids, oleic acid and linoleic 
acid, can increase tolerance to daptomycin (11, 12). In this study, we provide evidence 
that certain physical properties of oleic acid and linoleic acid confer protection against 
daptomycin. Specifically, we find that the cis bond in oleic acid as well as the carboxyl 
group for both oleic acid and linoleic acid are important for increased daptomycin 
tolerance.  
 
The cis bond in oleic acid is important for daptomycin tolerance. This study revealed 
that fatty acid induced daptomycin tolerance can be eliminated by changing the double 
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bond of C18∆9 from cis (oleic acid) to trans (elaidic acid). Bacterial membranes typically 
consist of saturated and unsaturated fatty acids in the sn1 and sn2 positions, respectively 
(22), although, this specific localization of fatty acids is not always the case (23). The 
presence of cis unsaturated fatty acids on phospholipids is believed to be critical for a 
number of reasons, but two of the primary reasons include providing a thermodynamically 
favorable membrane fluidity for membrane homeostasis (24) and for proper enzymatic 
activity of membrane bound proteins (25). Contrary to cis unsaturated fatty acids, trans 
unsaturated fatty acids can also be found in cell systems, but data from computer 
simulations and membrane fluidity experiments showed that trans unsaturated fatty acids 
impact membranes in a way similar to saturated fatty acids (26, 27). Previous data shows 
that when E. faecalis OG1RF is supplemented with saturated fatty acids, the cells do not 
have increased tolerance to daptomycin (11, 12) and so it is no surprise that a membrane 
packed with trans unsaturated fatty acids, that is biophysically similar to a membrane 
packed with saturated fatty acids, results in no increased daptomycin tolerance. However, 
despite our observations, other studies of daptomycin resistant strains have shown that 
decreased cell membrane fluidity appeared to be a contributing factor to resistance (10). 
 
E. faecalis OG1RF can incorporate polyunsaturated fatty acids but they may not 
induce daptomycin tolerance. Uptake or synthesis of unsaturated fatty acids containing 
one or two double bonds is a common feature of many bacterial cells (albeit, OG1RF 
shows no evidence of de novo synthesis of polyunsaturated fatty acids (11, 28, 29)). 
However, a limited number of bacteria (mostly marine) can produce acyl chains consisting 
of up to four double bonds and biochemical investigations show that a very specific array 
of genes (pfa) are responsible for the production of these tails (30). Although OG1RF 
does not produce polyunsaturated fatty acids (no evidence for pfa genes using pfaA from 
Photobacterium profundum as bait in BLAST), it can incorporate linoleic acid into its 
membrane and evidence suggests that it protects again daptomycin better than oleic acid 
(11). From this evidence, we examined whether the polyunsaturated fatty acid, linolenic 
acid could induce tolerance. We found that supplementation with linolenic acid did not 
increase daptomycin tolerance. Further, we found no evidence of this fatty acid in the 
membrane of OG1RF via GC-FAME likely due to insufficient detection sensitivity during 
45 
 
GC-FAME analysis. However, analysis of individual phospholipids (Figure 2.4) showed 
that several species of L-PG and PG, which could theoretically harbor linolenic acid (34:3. 
34:4 36:3, and 36:4), were increased at least 15-fold. These data suggest that it is indeed 
possible for linolenic acid to be incorporated, but we also see an abundance of free 
linolenic acid in the membrane. This could be a consequence of an inability of FakB to 
bind unsaturated fatty acids with three cis bonds due to steric hindrance (13). Or perhaps 
it is because OG1RF does not appear to contain the protein that could facilitates addition 
of polyunsaturated fatty acids onto phospholipids (1-acylglycerol-3-phosphate-O-
acyltransferase - AGPAT) (31). Additional work should be done to identify if the species 
that increase after linolenic acid supplementation (L-PG 34:3, 34:4) do indeed harbor 
linolenic acid. 
 
The carboxyl group on fatty acids is important for fatty acid induced daptomycin 
tolerance increases. The carboxyl group of fatty acids is an important molecular moiety 
necessary for attachment of the fatty acids to the glycerol backbone of glycerol-3-
phosphate (32). Further, phosphorylation of the carboxyl group by FakA is an apparent 
requirement for incorporation of exogenous fatty acids into phospholipid synthesis (13). 
Our data show that when the carboxyl group of either oleic acid or linoleic acid is replaced 
with an amide group, there is a loss of daptomycin tolerance. These data suggest that 
daptomycin tolerance under our experimental conditions relies on the incorporation of 
these fatty acids into phospholipids.  
Contrary to this argument is the observation that oleyl sulfate can increase tolerance 
to daptomycin after supplementation. This particular fatty acid does not contain a carboxyl 
group, so presumably it cannot be phosphorylated using the FakA mechanism. This 
appears to be the case because we do not see any change in the detected phospholipid 
species (Figure 2.4). Given that we find a large amount of this fatty acid free in the 
membrane (2,718-fold increase versus solvent control), it is possible that increased 
negative charge is preventing daptomycin from acting on the cell.  
 
Free fatty acids in the membrane. Supplementation with exogenous fatty acids, results 
in those fatty acids flipping into the membrane, which can be brought into the cell and 
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potentially incorporated onto membrane phospholipids or their derivatives. However, E. 
faecalis does not have the capacity to degrade fatty acids, so their fate is tied into the 
activity of fatty acid biosynthesis or phospholipid synthesis. If the fatty acid is not a good 
substrate for these processes, or there is excess fatty acid, toxicity may be the result (23). 
This is clear in how certain fatty acids impact generation time (Table 2.1). Interestingly, in 
our data, we observed that free linoleic acid is found at high levels in the membrane 
(92,006-fold increased), and significantly impacts generation time (~88 min) but is still 
able to increase tolerance to daptomycin. Conversely, linolenic acid, which is also found 
free to a high degree (28,334-fold increase), can impact generation time (~78 min), but 
does not increase tolerance to daptomycin. These data suggest that just because a fatty 
acid is found free in the membrane to a high abundance, does not result in increased 
daptomycin tolerance. Further, these data suggest that not all free fatty acids are equal 
in the membrane after supplementation and that some are more toxic to growth than 
others (linoleamide). An analysis of toxic fatty acids and the abundance of the fatty acid 
being free in the membrane may offer intriguing insights (12). 
Taken together, the data presented in this study aimed to identify the characteristics 
of oleic acid and linoleic acid that may contribute to induction of daptomycin tolerance. 
We observed that the cis bond at the 9th position of oleic acid was conferring a protective 
advantage against daptomycin while a trans bond at that position did not. Additionally, we 
tested if incorporation was important for host fatty acid induced tolerance. In this 
experiment, we used fatty acids that lack a carboxyl group and instead have an amide 
group, which has been proposed to lose the ability to be incorporated in S. aureus (21). 
Indeed, we found that oleamide and linoleamide failed to increase tolerance to 
daptomycin. Interestingly, we found that these particular fatty acids could be found in the 
membrane as incorporated fatty acids, but also as free fatty acids. Further experiments 
should be conducted to understand this particular outcome. 
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Appendix 
 
Supplemental Table 2.1 Fatty acids used in experiments. 
Oleic acid Elaidic acid 
 
 
 
 
Linoleic acid Linolenic acid 
  
Oleamide Oleyl sulfate 
  
Linoleamide  
 
Source: PubChem 
URL: https://pubchem.ncbi.nlm.nih.gov 
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CHAPTER III: Exogenous fatty acids protect Enterococcus faecalis 
from daptomycin induced membrane stress independent of the 
response regulator LiaR 
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Abstract 
Enterococcus faecalis is a commensal bacterium of the gastrointestinal tract that can 
cause nosocomial infections in immunocompromised humans. The hallmarks of this 
organism are its ability to survive in a variety of stressful habitats and, in particular, its 
ability to withstand membrane damage. One strategy used by E. faecalis to protect itself 
from membrane-damaging agents, including the antibiotic daptomycin, involves 
incorporation of exogenous fatty acids from bile or serum into the cell membrane. 
Additionally, the response regulator LiaR (a member of the LiaFSR [lipid II-interacting 
antibiotic response regulator and sensor] system associated with cell envelope stress 
responses) is required for the basal level of resistance E. faecalis has to daptomycin-
induced membrane damage. This study aimed to determine if membrane fatty acid 
changes could provide protection against membrane stressors in a LiaR-deficient strain 
of E. faecalis. We noted that despite the loss of LiaR, the organism readily incorporated 
exogenous fatty acids into its membrane, and indeed growth in the presence of 
exogenous fatty acids increased the survival of LiaR-deficient cells when challenged with 
a variety of membrane stressors, including daptomycin. Combined, our results suggest 
that E. faecalis can utilize both LiaR-dependent and -independent mechanisms to protect 
itself from membrane damage. 
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Introduction 
Enterococcus faecalis is a Gram-positive, facultative anaerobe that resides in the 
gastrointestinal tract of humans and many other mammalian species (1). Additionally, the 
organism is known to persist in the external environment for significant periods of time, 
demonstrating its ability to withstand a variety of changing conditions. Despite the 
commensal nature of E. faecalis, it is a significant contributor to nosocomial infections, 
including bloodstream, skin and soft tissue, and urinary tract infections, endocarditis, and 
meningitis in immunocompromised patients (2, 3). Eradication of E. faecalis, especially in 
regard to such infections, is challenging as the organism is inherently resistant to a variety 
of classes of antibiotics and has the ability to acquire additional resistance mechanisms 
via horizontal gene transfer (2, 4–6). Given this, enterococci are considered serious public 
health threats, and calls for new antibiotic therapies and surveillance are ongoing (7).  
Although resistant to many antibiotics, infections caused by E. faecalis have 
successfully been treated with the antibiotic daptomycin. Daptomycin is naturally 
synthesized by Streptomyces roseosporus (8, 9) and is FDA approved for the treatment 
of skin and soft tissue infections caused by susceptible Gram-positive bacteria. The 
antibiotic targets the cell membranes of Gram-positive bacteria, leading to membrane 
depolarization and eventual cell death (10, 11). More detailed studies on the mechanism 
of daptomycin action suggest that the antibiotic inserts into bacterial cell membranes in a 
calcium-dependent manner, which then allows monomers of daptomycin to oligomerize 
in the outer leaflet and finally translocate to the inner leaflet, forming pore-like structures 
(12). This sequence of events leads to a loss of membrane homeostasis, including 
leakage of ions from the cytoplasm (13, 14). Despite the success of this antibiotic, 
daptomycin resistant strains of enterococci have been isolated during patient treatment 
(6, 15). Characterization of daptomycin resistant isolates by whole-genome sequencing 
indicates that resistance develops by chromosomal mutations in genes related to cell 
membrane and envelope homeostasis (16, 17) rather than by acquisition of horizontally 
acquired elements.  
The ability to adapt and respond to environmental changes is essential for the survival 
of bacterial cells. Given that the cell envelope is constantly exposed to the environment, 
adaptive responses must be maintained or cell viability will be lost (18, 19). Across many 
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bacterial species, the regulatory process surrounding the cell envelope stress response 
consists of extracytoplasmic function (ECF) s factors and two-component systems (TCS) 
(20–22). In the Firmicutes (low G+C Gram-positive bacteria), numerous two- and three-
component systems respond to envelope damaging agents, including antimicrobial 
peptides and antibiotics (18, 23). One such example is the LiaFSR (lipid II-interacting 
antibiotic response regulator and sensor) system, which was first identified in Bacillus 
subtilis (24). In this system, LiaS is a membrane bound sensor histidine kinase, LiaR is 
the response regulator, and LiaF (25) is a membrane anchored negative regulator thought 
to affect the function of LiaS (25–27). LiaR was shown to regulate the expression of the 
liaIHGFSR locus, which, using an unknown mechanism, aids in the cellular response 
against cell envelope-targeting antibiotics and antimicrobial peptides (25).  
Genomic analysis of a daptomycin-susceptible and -resistant clinical strain pair of E. 
faecalis revealed that a codon deletion in liaF was responsible for the resistance 
phenotype (6, 15, 28). It is thought that this mutation increased the expression of LiaSR, 
activating the damage response pathway and effectively abolishing the bactericidal 
activity of the antibiotic (28, 29). Moreover, deletion of liaR, encoding the response 
regulator of the system, can render both E. faecalis and Enterococcus faecium 
hypersusceptible to daptomycin, independent of the strain background (30, 31).  
Our lab has recently discovered a previously unknown mechanism of environmentally 
induced tolerance to membrane-damaging agents (32). Specifically, we found that 
supplementing E. faecalis with bile or serum reduced susceptibility to high bile levels, 
sodium dodecyl sulfate (SDS), and daptomycin. Further analysis confirmed that E. 
faecalis was able to incorporate exogenous fatty acids from these supplements into its 
membrane, thus altering the fatty acid composition of the membrane. Supplementation 
with specific fatty acids, such as oleic acid, a dominant fatty acid found in bile and serum, 
confirmed that growth in the presence of fatty acids provided tolerance to these stressors 
(32).  
Given these observations, we sought to address the hypothesis that the presence of 
exogenous fatty acids triggers a LiaFSR-mediated envelope stress response in E. 
faecalis, improving the organism’s survival from membrane-damaging agents. Herein, 
however, we present data showing that supplementation of E. faecalis with exogenous 
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sources of fatty acids can reduce susceptibility to membrane stressors, including 
daptomycin, in the absence of liaR. These data suggest that the contribution of 
exogenous fatty acid incorporation to cell membrane protection is independent of the 
LiaFSR system. 
Materials and Methods 
Bacterial strains and growth conditions. Enterococcus faecalis strains OG1RF, 
OG1RF∆liaR (31), OG1RF∆liaR::liaR (31), and S613 and R712 (6, 15) were grown 
statically in brain heart infusion (BHI) medium at 37°C unless otherwise stated. Overnight 
cultures were used to inoculate medium to an optical density at 600 nm (OD600) of 0.01. 
Cultures were supplemented as indicated in the text with bovine bile (Sigma-Aldrich), 
pooled human serum (ICN Biomedicals), fatty acids (Sigma-Aldrich), or the solvent 
control (ethanol).  
GC-FAME preparation and analysis. Strains were grown as above with the 
supplements indicated in Table 3.1. At exponential phase (OD600 of ≈0.4), 10 to 12 ml 
of culture was centrifuged at 3,500 rpm for 10 min. Cell pellets were washed extensively 
twice with 1X phosphate-buffered saline (PBS). Pellets were subsequently stored at -
80°C and shipped on dry ice to Microbial ID, Inc. (Newark, DE) for gas chromatography-
fatty acid methyl ester (GC-FAME) analysis. Cells underwent saponification using a 
sodium hydroxide-methanol mixture and a hexane extraction before GC-FAME analysis 
as previously described (33). Results show averages and standard deviations for three 
independent cultures.  
Membrane challenge assays. Cells were harvested at mid-log phase (OD600 of ≈0.4), 
washed with 1X PBS, centrifuged, and resuspended in the appropriate challenge 
medium, as performed previously (32). For antibiotic treatment, cells were resuspended 
in BHI medium containing 100mM CaCl2 and either 10 µg/ml or 40 µg/ml daptomycin as 
indicated in the text. For bile treatment, cells were resuspended in an equivalent volume 
of 20% bovine bile. For SDS treatment, cells were resuspended in an equivalent volume 
of fresh BHI containing 0.05% SDS. Serial dilutions were plated onto BHI agar at 0, 15, 
30, and 60 min after resuspension in the challenge medium. The log ratio of survivors 
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over time was calculated for three biological replicates; the averages and standard 
deviations for each experiment are shown.  
Statistical analysis. Comparisons between the growth conditions, membrane content, 
and log ratio of survivors were determined using two-tailed, unpaired Student’s t tests as 
indicated in the text.  
1H NMR analyses. Stock solutions at 1.23 mM, 50 mM, and 100 mM of daptomycin (1.0 
mg, 617 nmol in 500 µl methanol-d4), oleic acid (7.0 mg, 24.8 µmol in 500 µl methanol-
d4), and calcium chloride (5.5 mg, 49.6 µmol in 500 µl methanol-d4), respectively, were 
prepared. The 1H NMR spectra were recorded on a VNMRS 500MHz NMR spectrometer 
(Varian NMR Systems, Palo Alto, CA). The proton nuclear magnetic resonance (1H NMR) 
experiments consisted of 128 scans using PRESAT solvent suppression peak selection. 
To examine a potential interaction between daptomycin and oleic acid, we looked at the 
spectra of mixtures containing either an equivalent concentration of daptomycin and oleic 
acid (1:1, daptomycin/oleic acid) or a mixture containing an excess of oleic acid (1:5, 
daptomycin/oleic acid). Each mixture was homogenized by vortexing, and the resulting 
solution was allowed to incubate at room temperature for 30 min. Following incubation, 
the 1H NMR experiment was repeated.  
To discover if calcium could induce an interaction between daptomycin and oleic acid, 
we also determined the spectra when calcium chloride was added. For all experiments, 
we used an overall molar ratio of 5:4 (calcium/daptomycin). The mixture was vortexed 
and allowed to incubate at room temperature for 30 min prior to the 1H NMR experiment 
to determine the baseline spectra of a calcium-daptomycin complex. For those 
experiments examining how this mixture may interact with oleic acid, the fatty acid was 
added following the incubation of calcium chloride and daptomycin. Oleic acid was added 
into the mixture at either a 1:1 or 1:5 molar ratio, the mixture was homogenized by 
vortexing and incubated at room temperature for 30 min, and then the 1H NMR experiment 
was repeated. 
Results 
Incorporation of exogenous fatty acids is similar in the presence or absence of liaR 
in E. faecalis. Previously, we demonstrated that growth in the presence of fatty acid 
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sources impacted the generation time of E. faecalis OG1RF (32). Most notably, growth in 
the presence of saturated fatty acids significantly increased the generation time of 
OG1RF compared to that in unsupplemented cultures. The organism also readily 
incorporated exogenous fatty acids into its membrane, even if those fatty acids negatively 
impacted growth. As the LiaFSR system has been shown to be important to the cell 
membrane stress response in enterococci, we wondered whether it contributed to our 
past observations. Thus, we examined the growth rates and membrane fatty acid 
contents of the parental OG1RF (control), the ∆liaR, and the genetically complemented 
∆liaR::liaR strains (31) in the presence and absence of exogenous fatty acid sources. It 
is important to note that E. faecalis does not possess genes for b-oxidation; therefore, the 
organism either incorporates exogenous fatty acids into its membrane or, in the case of 
exogenous short-chain fatty acids, potentially elongates such fatty acids (34, 35).  
In general, the growth rates and the membrane contents were similar for the three 
strains grown in BHI with a few notable differences. The generation times for all in 
unsupplemented medium was approximately 30 min (Table 3.1), which was increased to 
about 40 min when the strains were grown in the presence of ethanol (solvent control; 
final concentration of 0.2%). As shown in Table 3.2, the dominant fatty acids for all strains 
grown in BHI were cis-vaccenic acid (C18:1 cis 11, approximately 40%) and palmitic acid 
(C16:0, about 37%). While the overall membrane content was similar between the strains, 
we did note that the genetic complement (∆liaR::liaR) had significantly more palmitoleic 
acid (C16:1 cis 9) (P < 0.05) and less stearic acid (C18:0) (P < 0.05) than the wildtype and 
∆liaR strains. However, these differences did not influence the overall 
saturated/unsaturated ratio, which was close to 1 for all three strains (Table 3.2).  
As E. faecalis can readily cause wound infections and bacteremia, we examined both 
the growth rate and the membrane composition upon supplementation with 15% pooled 
human serum. The generation times were similar for the three strains with no statistical 
significance observed (Table 3.1). As with growth in unsupplemented medium, the 
dominant saturated fatty acid was palmitic acid (C16:0) for cultures grown in the presence 
of serum. Although not the major saturated fatty acid, stearic acid (C18:0) was 
approximately 2-fold higher (P < 0.001) in all strains in comparison to that for growth 
without serum. The greatest differences, however, were in the unsaturated fatty acid  
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Table 3.1. Exponential phase generation times of liaR and clinical strains in 
minutes. 
  
Medium constituent 
Strain 
BHIa Serumb Bilec C18:1 cis 9d Ethanole 
WT 32.2±0.5 36.5±0.8 32.7±1.9 39.6±0.7 42.1±1.0 
ΔliaR 28.7±1.3 36.2±3.4 33.2±3.4 35.2±3.3 38.0±4.1 
ΔliaR::liaR 31.4±2.9 34.1±2.8 27.5±3.4 35.2±2.4 35.0±1.9 
S613 29.7±2.7 31.0±3.4 48.1±3.5 27.1±1.5 31.1±2.6 
R712 29.4±2.5 36.0±1.2 40.8±3.8 30.0±2.2 38.0±1.0 
 
a BHI media was used in all cultures with supplements as indicated. 
b Pooled human serum was supplemented to a final concentration of 15%. 
c Bovine bile was supplemented to a final concentration of 0.2%. 
d Oleic acid was added to a final concentration of 20 μg/m. 
e Ethanol solvent control was added to a volume equivalent to the oleic acid 
supplement. 
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Table 3.2. Membrane analysis of wild-type and mutant strains during log phase growth. 
 
a Membrane content determined by GC-FAME analysis by Microbial ID, Inc.  Values represent average and standard deviations of three 
independent cultures.  ND indicates fatty acid was not detected. 
b Pooled human serum was supplemented to a final concentration of 15%. 
c Bovine bile was supplemented to a final concentration of 0.2%. 
d Oleic acid was added to a final concentration of 20 μg/mL. 
f  Others indicates fatty acids comprised <1% of the total membrane content. 
g Total fatty acid length ratios including both saturated and unsaturated fatty acids. 
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profiles upon supplementation. For cells grown with serum, the dominant unsaturated 
fatty acids were the eukaryote-derived oleic acid (C18:1 cis 9) and linoleic acid (C18:2 cis 9,12), 
which together constituted 40% of the total membrane content. There was a concomitant 
decrease in the amount of cis-vaccenic acid from approximately 40% in unsupplemented 
medium to less than 5% of the total membrane content in the presence of serum. These 
alterations did not alter the saturated/unsaturated ratios compared with those of 
unsupplemented cultures (Table 3.2). The lengths of the fatty acid tails were significantly 
longer for cells grown with serum (P < 0.001) (Table 3.2) as indicated by the ratio C10-
C17/C18-C20. These findings are consistent with the composition of fatty acids in serum 
(32) and indicative of their incorporation by E. faecalis. 
As E. faecalis naturally inhabits the intestine, we wanted to examine the effects of 
physiological levels of bile (0.2% bovine bile) upon growth and membrane content, as it 
too is a source of fatty acids that can be utilized by the organism (32). Growth with bile 
did not alter the generation times of any of the strains in comparison to growth in the 
absence of bile (Table 3.1). However, bile supplementation did impact the membrane 
contents of all strains examined. In all cases, palmitic acid (C16:0) remained the dominant 
saturated fatty acid and comprised approximately 42% of the membrane, which was a 
modest, but significant (P < 0.005), increase from growth in BHI alone. As was noted with 
serum supplementation, oleic acid (C18:1 cis 9) was the dominant unsaturated fatty acid, at 
approximately 40% of the total membrane content, and there was a concomitant reduction 
in the amount of cis-vaccenic acid (C18:1 cis 11). There was also an overall decrease in the 
total amounts of shorter-chain fatty acids, as indicated by the C10-C17/C18-C20 ratios (P < 
0.005) (Table 3.2) when all strains were grown with bile versus without bile. Despite these 
changes, the saturated/unsaturated fatty acid ratios were essentially unaltered among the 
wild-type, ∆liaR, and ∆liaR::liaR strains.  
We previously noted that E. faecalis can tolerate high levels of oleic acid (C18:1 cis 9) 
in culture and that this single fatty acid comprises the majority of the membrane content 
when supplemented at a final concentration of 20 µg/ml (32); indeed, this finding holds 
true even in a strain in which liaR is absent (Tables 3.1 and 3.2). For OG1RF and its 
derivatives examined here, oleic acid comprised approximately 70% of the membrane 
(Table 3.2). Essentially, cis-vaccenic acid (C18:1 cis 11), the native unsaturated C18 fatty 
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acid, was replaced entirely in the membrane by oleic acid. Oleic acid supplementation 
also markedly influenced the membrane saturated fatty acid composition. For all strains 
grown with exogenous oleic acid, the dominant saturated fatty acid was arachidic acid 
(C20:0) and not palmitic acid (C16:0) (Table 3.2), which is the dominant fatty acid found in 
cells grown without this supplement. This presence of arachidic acid was surprising, as it 
was not detected in unsupplemented cultures (see Discussion). Overall, the contributions 
of oleic acid and arachidic acid led to a membrane composition dominated by long-chain 
fatty acids, far different from what was observed in unsupplemented cultures (Table 3.2).  
Combined, these results suggest that induction of the LiaFSR response is not 
required for E. faecalis to incorporate exogenous fatty acids. Furthermore, the membrane 
content of the ∆liaR strain is not markedly altered from that of the parental strain under 
the conditions examined.  
 
Supplementation of growth medium with fatty acids can protect an OG1RF ∆liaR 
strain from membrane stress. Although the above results suggest that liaR is not 
needed for incorporation of exogenous fatty acids by E. faecalis, we decided to determine 
whether the lack of liaR impacted the ability of exogenous fatty acids to protect from 
membrane-damaging agents.  
To assess the impact of LiaR and the LiaFSR system on membrane stress 
responses, E. faecalis was grown in the presence or absence of fatty acid sources and 
then exposed to 20% bovine bile. Figure 3.1A shows that all strains were susceptible to 
20% bovine bile and that the ∆liaR strain was by far the most sensitive at all time points 
analyzed (15, 30, and 60 min). When strains were supplemented with 0.2% bile prior to 
challenge (providing a source of exogenous fatty acids), we observed an increase in 
survival for all strains. Importantly, supplementation of the medium with low levels of bile 
improved the survival of the deletion strain to the levels observed for wild-type OG1RF 
(Figure 3.1A). 
One of the main exogenous fatty acids incorporated into the membranes of these 
strains upon bile or serum supplementation was oleic acid (C18:1 cis 9) (Table 3.2). Our 
previous investigations demonstrated that supplementation solely with this fatty acid 
protected wild-type E. faecalis from membrane stress (32). We sought to determine if 
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supplementation with oleic acid alone could protect the ∆liaR strain from bile-induced 
stress. We examined this phenomenon by comparing cultures supplemented with 20 
µg/ml oleic acid to those without oleic acid prior to challenge with 20% bovine bile. The 
addition of oleic acid to the growth medium did provide tolerance to this membrane stress 
(Figure 3.1B). Nonetheless, the overall survival for all strains was best when they were 
supplemented with 0.2% bile than with 20 µg/ml oleic acid. As we observed with bile 
supplementation, growth with oleic acid was able to protect the ∆liaR strain from bile at a 
level equivalent to that observed in the wild-type or the complemented strains; thus, the 
inherent sensitivity of the mutant strain could be overcome.  
Given the improved survival of liaR-deficient E. faecalis when grown in medium 
supplemented with bile or oleic acid, we subsequently wanted to determine if such 
supplementation could protect from a different source of membrane damage. We grew 
strains in the presence of 0.2% bovine bile or 20 µg/ml oleic acid to exponential phase 
and then challenged the cells with 0.05% SDS (Figure 3.2A and 3.2B, respectively). 
Similar to the results for the 20% bile challenge, the cellular viability for all strains was 
increased in the presence of 0.05% SDS when cultures were supplemented with 0.2% 
bile or 20 µg/ml oleic acid. In the case of SDS treatment, however, the presence or 
absence of liaR had no impact on survival compared to that of wild-type or complemented 
strains, although modification of the membrane composition did indeed rescue all strains 
from SDS damage.  
 
Sensitivity to daptomycin of liaR-deficient E. faecalis is decreased upon 
supplementation with exogenous sources of fatty acids. To test whether the reduced 
daptomycin susceptibility mediated by exogenous sources of fatty acids (32) occurred 
through activation of the LiaFSR response, we examined daptomycin sensitivity in E. 
faecalis OG1RF∆liaR (31) grown in the presence or absence of fatty acid sources. The 
parental, deletion, and genetically complemented strains were grown to mid-log phase 
(OD600 of ≈0.4) in the presence of either 0.2% bile, 15% pooled human serum, or 20 µg/ml 
oleic acid and then exposed the cells to 10 µg/ml daptomycin. Figure 3.3 shows that the 
liaR deletion mutant was extremely susceptible to this concentration of daptomycin 
compared to the wild-type or ∆liaR::liaR strain. Survival against daptomycin challenge  
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Figure 3.1. Fatty acid supplementation protects liaR-deficient Enterococcus faecalis from high bile challenge.  
Shown are the averages ± standard deviations for n = 3. (A) Bile supplementation and challenge with 20% bile. All strains 
supplemented with 0.2% bile had statistically increased numbers of survivors versus those of their unsupplemented 
counterparts at all time points analyzed (P ≤ 0.001). (B) Oleic acid (OA) supplementation and challenge with 20% bile. All 
strains supplemented with 20 µg/ml OA had statistically increased numbers of survivors versus those of their 
unsupplemented counterparts at all time points analyzed (P ≤ 0.023). WT, wild type. 
 
 
 
 
A) B) 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Fatty acid supplementation protects liaR-deficient Enterococcus faecalis from sodium dodecyl sulfate 
challenge.  
Shown are the averages ± standard deviations for n = 3. (A) Bile supplementation and challenge with 0.05% sodium dodecyl 
sulfate (SDS). All strains supplemented with 0.2% bile had statistically increased numbers of survivors versus those of their 
unsupplemented counterparts at all time points analyzed (P ≤ 0.0001). (B) Oleic acid (OA) supplementation and challenge 
with 0.05% SDS. All strains supplemented with 20 µg/ml OA had statistically increased numbers of survivors versus those 
of their unsupplemented counterparts at all time points analyzed (P < 0.05).  
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was significantly improved in the ∆liaR strain by supplementation with either bile, serum, 
or oleic acid. However, supplementation of the deletion strain did not yield as many 
survivors as supplementation of the wild-type or genetically complemented strains. Taken 
together, these data suggest that exogenous fatty acids can reduce daptomycin 
susceptibility using a mechanism independent of the LiaFSR response, but modification 
of the fatty acid membrane composition does not completely overcome the need for liaR. 
 
Increased tolerance to daptomycin is not due to interaction with free fatty acids. 
Our data support the notion that the ∆liaR strain can incorporate exogenous fatty acids to 
a level similar to that of the wild-type strain, leading to better survival against membrane-
damaging agents, including the antibiotic daptomycin. As daptomycin is known to insert 
into membranes and has a fatty acid tail (decanoic acid [C10:0]) within its structure, we 
wanted to verify that our observations were not due to an interaction between daptomycin 
and free fatty acids. Additionally, since studies have demonstrated that the presence of 
calcium can alter the structure of daptomycin (13) and that the activity of the antibiotic is 
dependent upon calcium (36), we wanted to examine if calcium could potentially mediate 
an interaction between free fatty acids and daptomycin. To do this, we employed proton 
nuclear magnetic resonance (1H NMR) to observe the interactions of daptomycin, 
calcium, and oleic acid.  
Line broadening was observed in the spectrum containing calcium and daptomycin, 
which can be attributed to daptomycin aggregation, as previously reported (37). While the 
presence of calcium did impact the spectra of daptomycin (see Supplemental Figure 3.1 
and 3.2 in the supplemental material), we noted no additional line broadening or chemical 
shifts in the spectra if oleic acid was added (Figure 3.4).  
Thus, these data show that the lack of interaction between daptomycin and oleic acid 
indicates a role for altered cellular membranes and physiology in enhancing tolerance to 
daptomycin.  
 
Clinically isolated E. faecalis strains can incorporate exogenous fatty acids. Given 
the breadth of diversity of E. faecalis isolates (34), we wanted to ensure that our 
observations were not limited to OG1RF. Thus, we expanded our studies to include a 
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Figure 3.3. Fatty acid sources reduce daptomycin susceptibility in liaR deficient Enterococcus faecalis.  
Shown are the averages ± standard deviations for n=3. (A) Bile supplementation and challenge with 10 μg/ml daptomycin. 
All strains supplemented with 0.2% bile had statistically increased numbers of survivors versus those of their 
unsupplemented counterparts at all time points analyzed (P ≤ 0.002). (B) Serum supplementation and challenge with 10 
μg/ml daptomycin. All strains supplemented with 15% sera had statistically increased numbers of survivors versus those of 
their unsupplemented counterparts at all time points analyzed (P ≤ 0.011). (C) Oleic acid (OA) supplementation and 
challenge with 10 μg/ml daptomycin. All strains supplemented with 20 μg/ml OA had a statistically increased number of 
survivors versus those of their unsupplemented counterparts at all time points analyzed (P ≤ 0.002).  
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Figure 3.4. The addition of calcium does not direct an interaction between 
daptomycin and oleic acid.  
Shown is a superimposed image of five individual 1H NMR spectra, between 0.0 to 10.0 
ppm. The spectra are organized as follows, from top to bottom, a 1:5 mixture of 
daptomycin/oleic acid plus excess calcium (maroon), a 1:1 mixture of daptomycin/oleic 
acid plus excess calcium (red), 50 mM solution of oleic acid (blue), 1.2 mM daptomycin 
plus excess calcium (orange), and 1.23 mM daptomycin solution (black). All solutions 
were made using methanol-d4, and spectra were generated using a VNMRS 500 MHz 
instrument. Spectra were superimposed using MestReNova software. 
 
 
 
 
 
 
 
 
70 
 
clinical strain pair of daptomycin-susceptible and -resistant E. faecalis that were obtained 
from the bloodstream of a patient before and after daptomycin therapy (6). E. faecalis 
S613 is daptomycin susceptible (MIC of 0.5 to 1 µg/ml), and R712 is a daptomycin-
resistant derivative of S613 (MIC of 8 µg/ml) (15, 28). Previous analyses of these strains 
showed that the sole contributing factor for their differences in daptomycin susceptibility 
was a mutation in the negative regulator liaF (28). Given that these strains are true clinical 
isolates, we sought to examine their abilities to both incorporate exogenous fatty acids 
and respond to membrane stressors.  
Similar to OG1RF and its derivatives that were examined (Table 3.2), both clinical 
isolates had membranes dominated by palmitic acid (C16:0) and cis-vaccenic acid (C18:1 cis 
11) when grown in BHI (Table 3.3). However, the clinical isolates had significantly larger 
amounts of cis-vaccenic acid (P < 0.001) than OG1RF and its derivatives (5 to 10% 
increase) and, consequently, statistically lower levels of palmitic acid (P < 0.005); this was 
particularly true for R712. Despite these differences, the saturated/unsaturated ratio was 
not significantly different from that for OG1RF or its derivatives examined here.  
Upon supplementation with 15% serum, the clinical strains did not show major 
changes in generation times (Table 3.1). Additionally, their membrane contents, while 
altered from growth in unsupplemented medium, were similar to each other’s and to those 
of OG1RF. We again noted that the proportion of stearic acid (C18:0), while not dominant, 
did double for both strains when grown in serum, and we saw similar, if not higher, 
increases in OG1RF as well (Table 3.2 and Supplemental Table 3.1). The same decrease 
in cis-vaccenic acid (C18:1 cis 11), and concomitant increases in oleic acid (C18:1 cis 9) and 
linoleic acid (C18:2 cis 9, 12) observed in the OG1RF-derived strains were also present in the 
clinical isolates supplemented with serum.  
When supplemented with 0.2% bile, the clinical strains showed increases in 
generation times that were not observed in OG1RF or its derivatives (Table 3.1). 
However, this was statistically significant only for S613 (P < 0.001). The overall trends in 
membrane incorporation remained constant between the clinical isolates and OG1RF 
derivatives. In particular, we observed high levels of palmitic acid (C16:0) and also 
increases in stearic acid (C18:0) (Table 3.3 and Supplemental Table 3.2) for the clinical 
isolates that were similar to those observed with the OG1RF derivatives (Table 3.2).  
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Table 3.3. Membrane fatty acid analysis of clinical isolates during log phase growth. 
  Percent of total membrane content for indicated strain and supplement (Avg ± SD)a 
Strain S613 R712 S613 R712 S613 R712 S613 R712 
Fatty Acid BHI BHI Serumb Serumb Bilec Bilec C18:1 cis 9d C18:1 cis 9d 
C12:0 0.6 ± 0.1 0.7 ± 0.1 0.3 ± 0.0 0.3 ± 0.0 0.2 ± 0.2 0.3 ± 0.3 0.9 ± 0.0 1.1 ± 0.0 
C14:0 4.8 ± 0.1 3.7 ± 0.1 3.6 ± 0.1 2.4 ± 0.0 1.3 ± 0.1 1.6 ± 0.0 0.4 ± 0.1 0.6 ± 0.0 
C16:1 7.9 ± 0.2 7.8 ± 0.2 5.0 ± 0.2 4.7 ± 0.0 1.1 ± 0.1 1.7 ± 0.1 1.0 ± 0.2 1.4 ± 0.1 
C16:0 33.2 ± 0.2 28.2 ± 0.6 37.4 ± 0.6 36.6 ± 0.9 43.4 ± 0.7 43.0 ± 0.9 1.5 ± 0.2 1.9 ± 0.1 
C17:0 2OH 4.8 ± 0.2 6.1 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 ND ND ND ND 
C18:1 cis 9 ND ND 15.8 ± 0.8 18.6 ± 0.4 32.0 ± 1.6 38.1 ± 1.7 56.1 ± 3.4 57.8 ± 2.9 
C18:1 cis 11 44.1 ± 0.3 49.1 ± 0.2 7.5 ± 0.4 4.8 ± 0.2 3.1 ± 0.2 3.9 ± 0.2 0.5 ± 0.8 0.5 ± 0.8 
C18:0 3.4 ± 0.2 3.4 ± 0.2 7.4 ± 0.1 7.3 ± 0.1 10.8 ± 1.7 6.2 ± 1.4 0.5 ± 0.0 0.4 ± 0.0 
C20:0 ND ND 0.1 ± 0.1 ND 2.6 ± 0.4 0.4 ± 0.4 38.6 ± 4.6 36.4 ± 3.6 
C18:2 ND ND 18.9 ± 1.2 21.3 ± 1.4 ND ND ND ND 
C20:4 ND ND 1.1 ± 0.1 1.3 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 ND ND 
Othersf 0.6 ± 1.0 0.7 ± 1.1 2.4 ± 1.4 2.3 ± 1.6 5.1 ± 0.7 4.4 ± 0.8 0.4 ± 0.1 ND 
Sat:Unsat 0.8 ± 0.5 0.6 ± 0.8 1.0 ± 0.3 0.9 ± 0.5 1.6 ± 1.4 1.2 ± 1.1 0.7 ± 1.1 0.7 ± 1.0 
C10-C17:  
C18-C20g 
1.1 ± 0.01 0.9 ± 0.01 1.0 ± 0.1 0.9 ± 0.1 1.0 ± 0.3 1.0 ± 0.04 0.04 ± 0.0 0.05 ± 0.0 
a Membrane content determined by GC-FAME analysis by Microbial ID, Inc.  Values represent average and 
standard deviations of three independent cultures.  ND indicates fatty acid was not detected. 
b Pooled human serum was supplemented to a final concentration of 15%. 
c Bovine bile was supplemented to a final concentration of 0.2%. 
d Oleic acid was added to a final concentration of 20 μg/mL. 
f  Others indicates fatty acids comprised <1% of the total membrane content. 
g Total fatty acid length ratios including both saturated and unsaturated fatty acids. 
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The most dramatic difference between the clinical isolates and the OG1RF-derived 
strains can be seen in the membrane content of cultures supplemented with oleic acid 
(C18:1 cis 9). For the clinical strains, the membrane consisted of 57% oleic acid (Table 3.3), 
whereas for the OG1RF derivatives it was closer to 70% (Table 3.2). Again, for the clinical 
isolates, the dominant saturated fatty acid was C20:0 (arachidic acid), which made up more 
than 36% of the total membrane content. Interestingly, for OG1RF and its derivatives, as 
well as for the clinical isolates, this fatty acid was detected at significant levels only upon 
supplementation with oleic acid (C18:1 cis 9). It should be noted that the levels of arachidic 
acid in the clinical isolates (Table 3.3) were nearly double those observed for OG1RF and 
its derivatives (Table 3.2).  
In summary, similar to OG1RF and its derivatives, the clinical isolates S613 and R712 
readily incorporate exogenous sources of fatty acids into their membranes. Thus, despite 
genetic differences between the strains, the ability to incorporate fatty acids appears to 
be consistent.  
 
Specific fatty acid sources can alter sensitivity to membrane stress agents in 
clinical isolates. Our analysis of the membrane content of clinical isolates upon 
supplementation with fatty acid sources demonstrated that OG1RF is not unique in its 
ability to incorporate exogenous fatty acids (Table 3.3). Given these data, we sought to 
understand how these clinical isolates responded to membrane stress after exogenous 
fatty acid supplementation using the experimental design outlined before for OG1RF and 
its derivatives.  
We exposed the clinical strain pair, S613 and R712, to high levels of bovine bile 
(20%) when grown in the presence or absence of 0.2% bile or 20 µg/ml oleic acid. We 
noted increased survival across all time points assessed (15, 30, and 60 min) when 
cultures were supplemented with low levels of bile (Figure 3.5A). Surprisingly, 
supplementation with 20 µg/ml oleic acid was unable to protect either clinical isolate from 
the high bile challenge (Figure 3.5B), in stark contrast to what we observed with OG1RF 
and its derivatives (Figure 3.1B).  
Given these findings, we attempted to determine if supplementing this clinical pair 
with exogenous fatty acids could alter daptomycin susceptibility. We first supplemented 
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these strains with 0.2% bile until exponential phase and then exposed S613 or R712 to 
10 µg/ml or 40 µg/ml daptomycin, respectively. The rationale for this range of 
concentrations is the intrinsic daptomycin resistance of R712 (15). Interestingly, 
supplementation with 0.2% bile caused a significant increase in the ratio of S613 survivors 
for the entire time course when the strain was exposed to daptomycin (P < 0.001). 
Conversely, R712 had a moderate increase in survivors only after 60 min of exposure (P 
= 0.005) (Figure 3.6A). When the clinical isolates were supplemented with 15% pooled 
human serum, a result similar to that observed with 0.2% bile was documented for S613 
(Figure 3.6B). However, R712 did not appear to benefit from the fatty acids in serum.  
Given that growth in both bile and serum reduced the daptomycin sensitivity of S613, 
we wanted to investigate whether oleic acid alone also altered daptomycin susceptibility, 
as was observed for the OG1RF derivatives. As shown in Figure 3.6C, supplementation 
with oleic acid greatly reduced the sensitivity to daptomycin in S613 compared to that in 
unsupplemented cultures. We again examined the resistant isolate R712 under the same 
conditions and noted that growth in the presence of oleic acid decreased daptomycin 
susceptibility at a concentration of 40 µg/ml (Figure 3.6C). This effect was far greater than 
that observed by supplementation with bile or serum. Taken together, these data suggest 
that exogenous sources of fatty acids can indeed be taken up and incorporated and 
subsequently alter the susceptibility of E. faecalis clinical strains to membrane-damaging 
agents. 
Discussion 
Our previous data showed that E. faecalis OG1RF is able to incorporate exogenous fatty 
acids, which provide increased tolerance to membrane stressors such as bile, SDS, and 
daptomycin (32). These observations provided us with insights into how E. faecalis can 
utilize exogenous fatty acids from the host to reduce sensitivity to membrane stressors or 
membrane-damaging antibiotics. Moreover, the data described here suggest that 
increased tolerance to membrane stress was not a result of exogenous fatty acids 
activating the LiaFSR system. Using a clinical strain pair of E. faecalis clinical isolates, 
we also demonstrated that the ability to incorporate exogenous fatty acids, as well as the 
ability of such fatty acids to induce protection against membrane damage, is not limited  
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Figure 3.5. Fatty acid supplementation shows variable protection in daptomycin-sensitive (S613) and daptomycin-
resistant (R712) clinical pair isolates versus high bile challenge.  
Shown are the averages ± standard deviations for n = 3. (A) Bile supplementation and challenge with 20% bovine bile. All 
strains supplemented with 0.2% bile had statistically increased numbers of survivors versus those of their unsupplemented 
counterparts at all analyzed time points (P ≤ 0.001). (B) Oleic acid (OA) supplementation and challenge with 20% bovine 
bile. All strains supplemented with 20 μg/ml OA versus those of their unsupplemented counterparts were not statistically 
different at all time points analyzed (P value > 0.05).  
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Figure 3.6. Fatty acid sources demonstrate variable protection from daptomycin in daptomycin-sensitive (S613) 
and daptomycin-resistant (R712) clinical pair isolates.  
Shown are the averages ± standard deviations for n = 3. (A) Bile-supplemented S613 challenged with 10 μg/ml daptomycin 
or R712 challenged with 40 μg/ml daptomycin. S613 supplemented with 0.2% bile had statistically increased numbers of 
survivors versus those of its unsupplemented counterparts at all time points analyzed (P ≤ 0.037). (B) Serum 
supplementation and challenge with 10 μg/ml or 40 μg/ml daptomycin. S613 supplemented with 15% sera had a statistically 
increased number of survivors versus that of its unsupplemented counterpart at all time points analyzed (P values ≤ 0.0001), 
while the R712 supplemented cultures were not significantly different (P > 0.05). (C) Oleic acid (OA) supplementation and 
challenge with 10 μg/ml or 40 μg/ml daptomycin. All strains supplemented with 20 μg/ml OA had statistically increased 
numbers of survivors versus those of their unsupplemented counterparts at all time points analyzed (P ≤ 0.002).
A) B) C) 
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to laboratory strains of E. faecalis such as OG1RF. 
For all strains examined in this study, incorporation of exogenous fatty acids was 
conserved and fairly consistent across the genetic backgrounds. One interesting 
distinction, however, was the increased levels of arachidic acid (C20:0) in the membranes 
of the clinical isolate strains S613 and R712 compared to those of the OG1RF strains 
upon supplementation with oleic acid (Tables 3.2 and 3.3). The observation of arachidic 
acid in any of the strains was surprising: none of the strains produced detectable levels 
of this fatty acid when grown without supplementation. How then does supplementation 
with oleic acid lead to arachidic acid in the membrane? If E. faecalis were to elongate 
oleic acid, one would expect to see C20:1 cis 11 (38) and not arachidic acid (C20:0). It is 
possible that the cell is producing longer fatty acids through its de novo fatty acid 
biosynthetic pathway. The length of fatty acid tails during de novo biosynthesis is 
controlled via competition between the fatty acid acyltransferase and the fatty acid 
condensation (elongation) enzyme (39). Perhaps oleic acid supplementation directly or 
indirectly impacts the activity of one or both enzymes, leading to the observed increased 
fatty acid tail length. It is possible that the clinical isolates are more sensitive to these 
enzymatic changes, which might explain why we observe higher levels in these strains. 
Ongoing studies are geared to determine the source of this fatty acid. 
Although the membrane composition of OG1RFΔliaR is similar to that of the wild-type 
strain, the deletion strain is far more sensitive to 20% bile and daptomycin (Figure 
3.1 and 3.3). These data support the critical role of the LiaR-mediated membrane stress 
responses seen in other bacterial species (24, 27). However, supplementation with 
specific sources of exogenous fatty acids can increase survival of the ΔliaR strain when 
challenged with 20% bile or daptomycin (Figure 3.1A and C and Figure 3.3A and C). 
Thus, while liaR is required for the basal level of tolerance to high bile, the cell can 
circumvent this need if exogenous fatty acid sources are provided (Figure 3.1). In the 
case of daptomycin challenge, protection induced by fatty acids is independent of LiaFSR, 
but liaR is absolutely required for optimal membrane responses (Figure 3.3). These 
observations indicate that there are different cellular responses, depending on the type 
of membrane damage. The combined data also support previous findings that the host-
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derived fatty acid, oleic acid, can reduce membrane damage and even have a role in cell 
growth and survival (32, 40). 
Surprisingly, we did not observe increased sensitivity of the ΔliaR strain to SDS 
compared to that of the wildtype (Figure 3.2). This suggests that liaR is dispensable for 
the basal level of tolerance to SDS and again suggests that E. faecalis responds to 
different membrane stressors in unique ways. Previous work has shown that E. 
faecalis has an altered transcriptional response when exposed to bile versus SDS (41). 
It is likely that other components within bile, such as bile salts, may contribute to these 
altered responses, but further analysis is needed. 
Another interesting aspect of our study is that the supplementation of exogenous fatty 
acids to clinical isolates of E. faecalis may impact their tolerance to membrane damage 
(Figure 3.5 and 3.6). However, the ability of fatty acids to induce protection in the clinical 
isolates was not necessarily consistent with that in the OG1RF derivatives. For example, 
growth in oleic acid was unable to protect either R712 or S613 from high bile damage 
(Figure 3.5B), unlike what we observed for the derivatives of OG1RF (Figure 3.1B). It is 
not clear what differences may contribute to this observation. One possibility is 
differences in the amounts of arachidic acid (C20:0) between the strains (Tables 
3.2 and 3.3). For the clinical isolates, this fatty acid comprised >35% of the membrane 
content when the culture was supplemented with oleic acid, nearly double what was seen 
in the OG1RF derivatives This is reflected in the reduced ratio of C10-C17/C18-C20 fatty 
acids. This alteration might impact the expression or activity of membrane proteins (for 
example, efflux pumps) that may contribute to the overall sensitivity or resistance of the 
strains. More work is needed to elucidate the mechanism contributing to these 
observations. However, growth in oleic acid protects both S613 and R712 from 
daptomycin-induced damage (Figure 3.6C), mirroring what is seen in OG1RF derivatives. 
This indicates that damage induced by daptomycin and bile is not equivalent and that 
there are genetic or physiological differences between enterococcal strains in how they 
handle membrane-damaging agents. 
Overall, our results show that exogenous fatty acids impact membrane composition 
and the ability to survive a variety of membrane stressors. However, the mechanism by 
which fatty acids confer this protection is unclear. An altered membrane fatty acid profile 
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would likely impact the level, distribution, and potential activity of membrane-associated 
proteins that may contribute to survival. Additionally, it is not clear what other metabolic 
processes may be impacted by shifting from de novo fatty acid biosynthesis for the 
generation of membranes to the use of exogenous fatty acids. These observations and 
the underlying mechanism(s) of fatty acid-induced membrane protection are critically 
important for understanding the host-pathogen interaction and bacterial response to 
antimicrobial peptides due to the abundance of free fatty acids. E. faecalis is a 
commensal organism that has access to fatty acids located in bile and serum and is 
naturally tolerant to these compounds. In the human host, E. faecalis from the gut may 
enter different compartments and alter their membranes in order to succeed in a hostile 
environment. Fatty acids in serum and tissues might help the bacterium survive 
membrane stressors driven by the innate immune system (i.e., antimicrobial peptides). 
A growing number of studies are demonstrating that the microbes within the host, 
both commensal organisms and pathogens, are capable of utilizing host metabolites, 
including fatty acids. Utilization of these sources significantly impacts the microbes, 
leading to altered physiology, gene expression, and possibly virulence (42). These 
studies, in conjunction with our previous findings, demonstrate that host fatty acids can 
induce protection from membrane stressors, including antibiotics. It is worth noting, 
however, that measurements of MICs of antimicrobials are not often performed in the 
presence of host fatty acid sources (43). It is worth considering further how the host 
environment may lead to an altered sensitivity to such damaging agents and to take into 
account the host environment when such analyses are performed. 
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Appendix 
Supplemental materials and methods 
Proton Nuclear Magnetic Resonance (1H NMR) Profile 
 
1.23 mM Daptomycin: 1H NMR (500 MHz, Methanol-d4) δ 7.65 (dd, J = 8.3, 1.5 Hz, 1H), 
7.54 (dt, J = 7.9, 1.0 Hz, 1H), 7.32 (dd, J = 8.2, 0.9 Hz, 1H), 7.21 (ddd, J = 8.4, 6.9, 1.4 
Hz, 1H), 7.15 (s, 1H), 7.07 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 6.98 (ddd, J = 8.0, 7.0, 1.0 
Hz, 1H), 6.70 (dd, J = 8.5, 1.1 Hz, 1H), 6.54 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 5.45 – 5.39 
(m, 1H), 4.72 (t, J = 6.7 Hz, 1H), 4.64 (t, J = 6.7 Hz, 1H), 4.63 – 4.58 (m, 2H), 4.54 (d, J 
= 3.4 Hz, 1H), 4.52 (d, J = 7.6 Hz, 1H), 4.48 (t, J = 5.4 Hz, 1H), 4.36 – 4.30 (m, 1H), 
4.28 (t, J = 7.1 Hz, 1H), 3.99 (d, J = 4.3 Hz, 1H), 3.94 (d, J = 11.7 Hz, 2H), 3.86 (qd, J = 
11.0, 9.9, 4.2 Hz, 3H), 3.51 (q, J = 7.0, 4.6 Hz, 1H), 3.24 (dd, J = 14.3, 7.8 Hz, 1H), 3.12 
(dd, J = 14.3, 7.3 Hz, 1H), 2.98 – 2.79 (m, 5H), 2.74 (dt, J = 15.9, 7.5 Hz, 3H), 2.69 – 
2.58 (m, 3H), 2.40 (dd, J = 15.6, 6.5 Hz, 1H), 2.30 – 2.12 (m, 5H), 1.97 (d, J = 0.7 Hz, 
1H), 1.91 – 1.76 (m, 2H), 1.72 (q, J = 7.6 Hz, 2H), 1.50 (q, J = 7.6 Hz, 2H), 1.38 – 1.27 
(m, 9H), 1.27 – 1.14 (m, 16H), 0.97 (d, J = 6.9 Hz, 3H), 0.89 (t, J = 7.0 Hz, 4H). 
 
50 mM Oleic Acid: 1H NMR (500 MHz, Methanol-d4) δ 5.34 (ddd, J = 5.7, 4.4, 1.1 Hz, 
2H), 2.27 (t, J = 7.4 Hz, 2H), 2.03 (q, J = 5.8 Hz, 4H), 1.59 (p, J = 7.3, 7.3 Hz, 2H), 1.39 
– 1.24 (m, 20H), 0.89 (t, J = 6.9 Hz, 3H). 
 
1.20 mM Daptomycin and 1.20 mM Oleic Acid: 1H NMR (500 MHz, Methanol-d4) δ 7.66 
(d, J = 8.1 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.21 (t, J = 8.0 Hz, 
1H), 7.14 (s, 1H), 7.07 (t, J = 7.5 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.70 (d, J = 8.4 Hz, 
1H), 6.54 (t, J = 7.6 Hz, 1H), 5.46 – 5.39 (m, 1H), 5.34 (t, J = 4.9 Hz, 1H), 4.70 (t, J = 
6.7 Hz, 1H), 4.67 – 4.52 (m, 4H), 4.47 (s, 1H), 4.37 – 4.26 (m, 2H), 4.06 – 3.97 (m, 1H), 
3.94 (d, J = 15.3 Hz, 2H), 3.88 (d, J = 16.6 Hz, 3H), 3.52 (s, 2H), 3.44 (p, J = 1.6 Hz, 
2H), 3.16 (p, J = 1.7 Hz, 2H), 3.12 (dd, J = 14.4, 7.3 Hz, 1H), 2.97 – 2.91 (m, 2H), 2.89 
– 2.66 (m, 4H), 2.66 – 2.58 (m, 2H), 2.39 (dd, J = 15.5, 6.6 Hz, 1H), 2.33 – 2.13 (m, 6H), 
2.06 – 1.99 (m, 2H), 1.92 – 1.78 (m, 1H), 1.72 (q, J = 7.5 Hz, 2H), 1.65 – 1.56 (m, 1H), 
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1.52 – 1.45 (m, 2H), 1.38 – 1.27 (m, 20H), 1.23 (dd, J = 16.8, 5.5 Hz, 15H), 0.98 (d, J = 
6.9 Hz, 4H), 0.89 (td, J = 6.9, 5.0 Hz, 5H). 
 
1.10 mM Daptomycin and 5.50 mM Oleic Acid: 1H NMR (500 MHz, Methanol-d4) δ 7.66 
(d, J = 8.1 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.24 – 7.18 (t, J = 
8.0 Hz, 1H), 7.14 (s, 1H), 7.07 (t, J = 7.5 Hz, 1H), 6.98 (t, J = 7.5 Hz 1H), 6.70 (d, J = 
8.1 Hz, 1H), 6.54 (t, J = 7.6 Hz, 1H), 5.46 – 5.39 (m, 1H), 5.34 (ddd, J = 5.6, 4.4, 1.1 Hz, 
10H), 4.71 (m, 1H), 4.62 (t, J = 6.4 Hz, 1H), 4.54 (s, 2H), 4.47 (s, 1H), 4.37 – 4.26 (m, 
1H), 4.02 (d, J = 16.2 Hz, 1H), 3.94 (d, J = 15.0 Hz, 2H), 3.85 (d, J = 15.8 Hz, 3H), 3.52 
(s, 2H), 3.44 (p, J = 1.7 Hz, 2H), 3.16 (p, J = 1.6 Hz, 2H), 2.94 (s, 3H), 2.89 – 2.67 (m, 
9H), 2.63 (d, J = 15.3 Hz, 2H), 2.40 (dd, J = 15.5, 6.4 Hz, 1H), 2.25 (t, J = 7.5 Hz, 10H), 
2.18 (t, J = 7.6 Hz, 3H), 2.07 – 1.99 (m, 20H), 1.76 – 1.69 (m, 2H), 1.64 – 1.55 (m, 10H), 
1.49 (s, 3H), 1.38 – 1.27 (m, 100H), 1.27 – 1.19 (m, 12H), 0.98 (d, J = 6.9 Hz, 4H), 0.89 
(td, J = 6.9, 5.3 Hz, 18H). 
 
1.21 mM Daptomycin and 1.64 mM Calcium Chloride:1H NMR (500 MHz, Methanol-d4) 
δ 7.65 (dd, J = 8.3, 1.5 Hz, 1H), 7.53 (s, 1H), 7.30 (s, 1H), 7.24 (s, 1H), 7.15 (s, 1H), 
7.07 (t, J = 7.6 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.75 (d, J = 10.6 Hz, 1H), 6.58 (s, 1H), 
5.45 – 5.39 (m, 1H), 4.72 (t, J = 6.7 Hz, 1H), 4.64 (t, J = 6.7 Hz, 1H), 4.63 – 4.58 (m, 
2H), 4.54 (d, J = 3.4 Hz, 1H), 4.52 (d, J = 7.6 Hz, 1H), 4.49 (s, 1H), 4.36 – 4.30 (m, 1H), 
4.29 (s, 1H), 4.02 (s, 1H), 3.94 (m, 2H), 3.86 (m, 3H), 3.53 (m, 1H), 3.31 (dd, J = 7.3, 
2.2 Hz, 1H), 3.12 (m, 1H), 2.96-2.84 (s, 5H), 2.77 (s, 3H), 2.69 – 2.58 (m, 3H), 2.38 (d, J 
= 18.0 Hz, 1H), 2.30 – 2.12 (m, 5H), 1.95 (s, 1H), 1.77 (s, 2H), 1.72 (m, 2H), 1.45 (s, 
2H), 1.33 (m, 9H), 1.29 – 1.13 (m, 16H), 0.95 (s, 3H), 0.89 (t, J = 7.1 Hz, 4H). 
 
1.20 mM Daptomycin, 1.60 mM Calcium Chloride, and 1.20 mM Oleic Acid: 1H NMR 
(500 MHz, Methanol-d4) δ 7.71 (s, 1H), 7.53 (s, 1H), 7.30 (s, 1H), 7.24 (s, 1H), 7.07 (t, J 
= 7.6 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.74 (s, 1H), 6.58 (s, 1H), 5.46 – 5.39 (m, 1H), 
5.34 (m, 1H), 4.70 (t, J = 6.7 Hz, 1H), 4.67 – 4.52 (m, 4H), 4.49 (s, 1H), 4.29 (s, 2H), 
4.01 – 3.92 (m, 3H), 3.79 (s, 3H), 3.54 – 3.12 (m, 7H), 2.96 (s, 2H), 2.87 – 2.80 (m, 4H), 
2.66 – 2.58 (m, 2H), 2.38 (d, J = 18.2 Hz, 1H), 2.34 – 2.13 (m, 6H), 2.06 – 1.97 (m, 2H), 
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1.94 – 1.78 (m, 1H), 1.77 (s, 2H), 1.60 – 1.45 (m, 3H), 1.35 – 1.25 (m, 20H), 1.24 (s, 
15H), 1.19 (s, 2H), 1.13 (s, 2H), 0.89 (t, J = 7.1 Hz, 4H). 
 
1.05 mM Daptomycin, 1.45 mM Calcium Chloride, and 5.8 mM Oleic Acid: 1H NMR (500 
MHz, Methanol-d4) δ 7.70 (s, 1H), 7.53 (s, 1H), 7.30 (s, 1H), 7.24 (s, 1H), 7.14 (s, 1H), 
7.07 (t, J = 7.6 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.74 (s, 1H), 6.58 (s, 1H), 5.34 (ddd, J = 
5.7, 4.5, 1.1 Hz, 10H), 4.71 (m, 1H), 4.63 (t, J = 6.4 Hz, 1H), 4.54 (m, 2H), 4.48 (s, 1H), 
4.29 (s, 1H), 4.02 (d, J = 16.5 Hz, 1H), 3.79 – 3.40 (m, 7H), 3.21 (td, J = 5.0, 2.4 Hz, 
2H), 2.96 (s, 3H), 2.87 – 2.62 (m, 11H), 2.40 (s, 1H), 2.27 – 2.11 (m, 10H), 2.03 – 1.95 
(m, 20H), 1.77 (s, 2H), 1.63 – 1.56 (m, 10H), 1.45 (s, 2H), 1.36 – 1.26 (m, 100H), 1.24 
(s, 15H), 1.19 (s, 3H), 1.13 (s, 2H), 0.95 (s, 4H), 0.89 (td, J = 7.0, 4.8 Hz, 15H). 
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a Membrane content determined by GC-FAME analysis by Microbial ID, Inc. 
Values represent average and standard deviations of three independent 
cultures.  ND indicates fatty acid was not detected. 
e Ethanol solvent control was added to a final concentration of 0.2%. 
g Total fatty acid length ratios including both saturated and unsaturated fatty acids. 
 
 
 
 
 
 
 
 
 
Supplemental Table 3.1. Membrane analysis of wild 
type and mutant strains during log phase growth. 
  
Percent of total membrane content for 
indicated strain and supplement (Avg ± 
SD)a 
Strain WT ΔliaR ΔliaR::liaR 
Fatty Acid Ethanole Ethanole Ethanole 
C12:0 1.4 ± 1.1 1.3 ± 0.9 0.9 ± 0.1 
C14:0 4.6 ± 0.4 4.2 ± 0.2 6.4 ± 0.1 
C16:1 5.7 ± 0.3 5.5 ± 0.8 8.7 ± 0.1 
C16:0 39.8 ± 0.5 42.7 ± 1.8 37.5 ± 0.1 
C17:1 ND ND ND 
C17:0 2OH 7.5 ± 1.0 5.3 ± 3.1 5.9 ± 0.3 
C18:1 cis 9 0.3 ± 0.6 0.7 ± 1.3 0.6 ± 0.5 
C18:1 cis 11 34.0 ± 1.0 32.6 ± 1.1 35.7 ± 0.1 
C18:0 5.6 ± 0.1 6.9 ± 0.8 3.2 ± 0.1 
C20:0 ND ND ND 
C18:2 ND ND ND 
Othersf 0.7 ± 0.3 0.4 ± 0.4 0.7 ± 0.2 
Sat:Unsat 1.3 ± 1.0 1.4 ± 1.1 1.1 ± 0.6 
C10-C17:C18-C20g 1.5 ± 0.3 1.5 ± 0.03 1.5 ± 0.1 
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a Membrane content determined by GC-FAME analysis by Microbial ID, Inc.  
Values represent average and standard deviations of three independent 
cultures.  ND indicates fatty acid was not detected. 
e Ethanol solvent control was added at a final concentration of 0.2%. 
g Total fatty acid length ratios including both saturated and unsaturated fatty acids. 
 
 
 
 
 
 
 
 
Supplemental Table 3.2. Membrane fatty acid 
analysis of clinical isolates during log phase 
growth. 
  
Percent of total membrane content for 
indicated strain and supplement  
(Avg ± SD)a 
Strain S613 R712 
Fatty Acid Ethanole Ethanole 
C12:0 1.0 ± 0.0 0.7 ± 0.1 
C14:0 5.5 ± 0.1 3.8 ± 0.2 
C16:1 8.0 ± 0.1 7.8 ± 0.4 
C16:0 36.4 ± 0.2 29.3 ± 1.0 
C17:0 2OH 4.4 ± 0.3 4.5 ± 3.9 
C18:1 cis 9 0.9 ± 0.1 ND 
C18:1 cis 11 39.1 ± 0.4 50.0 ± 2.1 
C18:0 3.8 ± 0.1 3.5 ± 0.1 
C20:0 ND ND 
C18:2 ND ND 
C20:4 ND ND 
Othersf 0.4 ± 0.7 ND 
Sat:Unsat 1.0 ± 0.4 0.6 ± 0.6 
C10-C17:C18-C20g 1.3 ± 0.02 0.9 ± 0.08 
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Supplemental Figure 3.1. Mixing 1:1 daptomycin and oleic acid reveals no 
observable interaction.   
Visual comparison of three individual 1H NMR spectra, between 0.0 to 10.0 ppm, shows 
no interaction between daptomycin and oleic acid.  The top spectra (blue) represents a 
1mM solution of oleic acid, the middle spectra (black) represents a 340μM solution of 
daptomycin, and the bottom spectra (red) represents a 1:1 mixture of daptomycin:oleic 
acid.  All solutions were made using methanol-d4, and spectra were generated using a 
VNMRS 500 MHz instrument.  Spectra were superimposed using MestReNova software. 
 
  
 
 
 
 
 
 
 
1:1 Dap:OA 
Daptomycin 
Oleic Acid 
1) 1mM Oleic Acid 
2) 340μM Daptomycin 
3) 338μM Daptomycin and                                                      
338μM Oleic Acid     
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Supplemental Figure 3.2. Excess oleic acid reveals no observable interaction when 
mixed with daptomycin.   
The overlap of three individual 1H NMR spectra, between 0.0 to 10.0 ppm, shows no 
spatial interaction with daptomycin in the presence of excess oleic acid.  The top spectra 
(blue) represents a 1mM solution of oleic acid, the middle spectra (black) represents a 
340μM solution of daptomycin, and the bottom spectra (red) represents a 1:5 mixture of 
daptomycin:oleic acid.  All solutions were made using methanol-d4, and spectra were 
generated using a VNMRS 500 MHz instrument.  Spectra were superimposed using 
MestReNova software. 
 
1:5 Dap:OA 
Daptomycin 
Oleic Acid 
1) 1mM Oleic Acid 
2) 340μM Daptomycin 
3) 334μM Daptomycin and 
1.67mM Oleic Acid 
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CHAPTER IV: Host associated fatty acids induce global lipid 
composition alterations in Enterococcus faecalis 
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Future Publication Note 
A version of this chapter will eventually be submitted for publication. 
 
Host associated fatty acids induce global lipid composition alterations in Enterococcus 
faecalis. 2018/2019. John R. Harp, Eric D. Tague, William T. Brewer, Brittni M. Woodall, 
Katarina A. Jones, Shawn R. Campagna, and Elizabeth M. Fozo 
 
Experiments were conducted by John Harp, with the exception of: GC-FAME which was 
completed by Microbial ID; cell growth for GC-FAME with help from Will Brewer, and 
Elizabeth Fozo; targeted mass spectrometry analysis completed by Eric Tague and 
Brittany Woodall with the assistance of Shawn Campagna. John Harp and Elizabeth Fozo 
wrote the manuscript. 
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Abstract 
Enterococcus faecalis can incorporate exogenous host fatty acids, which increases 
tolerance to membrane stressors like daptomycin, but the mechanism explaining this 
observation is unknown. Using quantitative targeted mass spectrometry, we found that 
the abundance of targeted lysyl-phosphatidylglycerol (L-PG) species increases and the 
abundance of targeted phosphatidylglycerol and cardiolipin species decreases after 
supplementing E. faecalis with the host fatty acids, oleic acid and linoleic acid. Deletion 
of the mprF2 gene, resulted in a loss of L-PG, however addition of oleic acid or linoleic 
acid still increased daptomycin tolerance. Further, deletion of cls1 and cls2, reduced the 
amount of cardiolipin produced by E. faecalis, but did not eliminate production completely. 
While, a ∆cls1/∆cls2 deletion strain was more sensitive to daptomycin, supplementation 
with host fatty acids could still induce tolerance. These data suggest that exposure to the 
host fatty acids, oleic acid and linoleic acid, cause changes to the phospholipid profile of 
E. faecalis, but that mprF2, cls1, and cls2 are not involved in host fatty acid mediated 
daptomycin tolerance. 
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Introduction 
Enterococcus faecalis is a Gram-positive commensal in the gastrointestinal tract of 
humans, but can colonize in-dwelling medical devices, infect wounds, and cause 
septicemia if its niche expands due to antibiotic treatment or the compromised 
immunostatus of the host (1). Unfortunately, E. faecalis is inherently resistant to many 
therapeutics leaving few options for treatment. One treatment that is used to combat 
multi-drug resistant enterococci is the calcium-dependent lipopeptide antibiotic, 
daptomycin. Although the specific details of the action mechanism are not validated, 
daptomycin inserts a 10-carbon containing fatty acid tail into the Gram-positive bacterial 
membrane in association with phosphatidylglycerol, then oligomerizes with other 
daptomycin monomers to destabilize the membrane and cause cell death (2–5). Even 
with use only for multidrug resistant cases, daptomycin resistant strains have been 
isolated in the clinic (6). Sequencing of these resistant strains, along with in vitro evolved 
daptomycin resistant strains, showed the presence of several genetic mutations, including 
within liaF (of the LiaFSR three component system), cls (cardiolipin synthase), and gdpD 
(glycerophosphoryl diester phosphodiesterase) genes (6, 7). 
Our lab discovered that supplementing E. faecalis with host sources of exogenous 
fatty acids, such as bile (exposed to during commensal state) or serum (pathogenic state), 
increased the tolerance to general membrane stress agents as well as daptomycin (8). 
Moreover, this tolerance occurred only upon supplementing E. faecalis OG1RF with host-
derived oleic acid (C18:1 cis 9) or linoleic acid (C18:2 cis 9, 12) (9). As LiaFSR responses have 
been implicated in tolerance to daptomycin, we hypothesized that exogenous fatty acids 
triggered a LiaFSR mediated stress response (10). Using a liaR deficient strain of E. 
faecalis OG1RF, we found that exogenous fatty acids still provided increased protection 
against general membrane stressors or daptomycin (11). Consequently, induction of 
LiaFSR was not involved in increasing tolerance to daptomycin after supplementation.  
An alternative hypothesis to explain the observed tolerance to membrane stressors 
after host fatty acid supplementation was that the membrane phospholipid composition 
was altered. This is supported by several observations demonstrating that changes in 
phospholipid composition (12), localization of cardiolipin (13) and mutations in the gene 
that encodes cardiolipin synthase (14) can contribute to daptomycin resistance in 
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enterococci. Further, increased lysinylation of phosphatidylglycerol has been attributed to 
cationic antimicrobial peptide resistance (15, 16). 
Given these observations, we hypothesized that supplementation with host fatty 
acids alters the phospholipid composition, thus resulting in increased membrane stress 
tolerance. Herein, we present data showing that supplementation of E. faecalis with host 
fatty acids alters the phospholipid profile, specifically by increasing the proportion of lysyl-
phosphatidylglycerol (L-PG) species and decreasing the proportion of 
phosphatidylglycerol (PG) species and cardiolipin (CL) species. To test if alterations to L-
PG or CL were specifically contributing, we deleted the genes responsible for production 
of these phospholipids, mprF2 and cls1/cls2 respectively. We found that strains lacking 
mprF2, cls1, cls2, cls1/cls2, and cls1/cls2/mprF2 still had increased tolerance to 
daptomycin even though their membrane phospholipid content was altered from the 
parental strain. These data suggest that supplementation with the host fatty acids, oleic 
acid and linoleic acid, induce lipid alterations, but changes in specific L-PG or CL species 
are not responsible for induced daptomycin tolerance. 
Materials and Methods 
Bacterial growth conditions. E. faecalis strains were grown statically in brain heart 
infusion medium (BHI; BD Difco) at 37°C. For the determination of growth rate and 
generation time, overnight cultures were diluted into fresh BHI medium to an optical 
density at 600 nm (OD600) of 0.01 with supplements added to the final concentration as 
indicated in the text and allowed to grow until stationary phase. For all other fatty acid 
exposure experiments, overnight cultures were diluted into fresh BHI medium as 
described above and grown until an OD600 of ~0.25. Fatty acid supplements were then 
added at concentrations indicated in the text and incubated at 37°C for 30 minutes (9). 
All fatty acids and chemicals were purchased from Sigma-Aldrich unless noted otherwise. 
Escherichia coli strains were grown in BHI medium at 37°C with shaking. Counter-
selection was performed on MM9YEG agar plates (Final concentration: 1X M9 salts, 
0.25% yeast extract, 250µg mL-1 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-
gal), and 0.5% glucose) containing 10mM p-Cl-phenylalanine (p-Cl-Phe). Antibiotics were 
used at the following concentrations when needed: erythromycin, 10µg mL-1 (E. faecalis) 
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or 100µg mL-1 (E. coli); spectinomycin, 1000µg mL-1; fusidic acid, 25 µg mL-1; rifampicin, 
250 µg mL-1.  
Generation of bacterial deletion strains. The strains generated in this study are listed 
in Supplemental Table 4.1 and the sequence of all nucleotide primers used in this study 
are in Supplemental Table 4.2. Generation of deletion strains of E. faecalis OG1RF was 
through the method of Kristich et al. (17). To delete the mprF2 gene and two predicted 
cardiolipin synthase genes, ~1000bp flanking regions of OG1RF_RS03930 (mprF2), 
OG1RF_RS01975 (cls1) or OG1RF_RS06840 (cls2) were amplified from E. faecalis 
OG1RF genomic DNA. The two products for each gene region were then spliced together 
using the external primers (18). Primers containing complementary overlaps with the 
spliced gene regions were used to amplify pCJK47 (17). The amplified inserts and vectors 
were assembled using NEB Gibson Assembly Master Mix. E. coli strain EC1000 was then 
transformed and colonies selected for erythromycin resistance. Once verified, pMPRF2 
(to generate ∆OG1RF_RS03930 – mprF2), pJRH1 (to generate ∆OG1RF_RS01975 – 
cls1) or pJRH2 (to generate ∆OG1RF_RS06840 – cls2) was transformed into an E. 
faecalis conjugative donor strain (CK111/pCF10-101). After clonal selection, conjugative 
donors containing pMPRF2, pJRH1 or pJRH2 were mixed with an OG1RF recipient at a 
ratio of 1 part donor to 9 parts recipient. After conjugation, cells were placed on recipient 
(rifampicin, fusidic acid, erythromycin and X-gal) or donor (spectinomycin and 
erythromycin) selection media. Blue colonies from the recipient plates were then re-
isolated on the same selective medium. Confirmed colonies were then grown to stationary 
phase in BHI in the absence of selection, diluted, and then isolated on MM9YEG. White 
colonies were then tested for erythromycin sensitivity and sequenced for verification.  
GC-FAME preparation and analysis. Cells were grown to log phase using the 
experimental strategies outlined in bacterial growth conditions. 15 mL aliquots of cells 
were washed twice with 10 mL of 1X phosphate buffered saline (PBS), pelleted, and 
stored at -80°C prior to shipment to Microbial ID, Inc. (Newark, DE). Cells were then 
subjected to saponification with a sodium hydroxide-methanol mixture, a methylation 
step, and hexane extraction prior to GC-FAME analysis (19). 
Membrane challenge assays. Cells were diluted to an OD600 of 0.01 in BHI medium, 
incubated until exponential phase (OD600 of ~ 0.225-0.25), and then supplemented with 
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either solvent control, 20 µg mL-1 oleic acid (C18:1 cis-9) or 10 µg mL-1 linoleic acid (C18:2 cis-
9, 12) for 30 minutes (9). 10 mL of cells were harvested and washed twice with 10 mL of 
1X PBS and then resuspended in BHI (for SDS challenge) or BHI containing 1.5mM CaCl2 
(for daptomycin challenge) and treated with either a final concentration of 0.05% SDS or 
15 µg mL-1 of daptomycin. Serial dilutions were plated onto BHI agar at 0, 15, 30, and 60 
minutes after exposure to the indicated membrane stressor. Additionally, prolonged 
exposure to SDS or daptomycin was performed, with aliquots of cells plated at 0, 1, 2, 4, 
and 18 hours post addition of membrane stressor. The log ratio of survivors over time 
was calculated for three biological replicates and shown are the averages and standard 
deviations for each experiment. 
Phospholipid Extraction for Mass Spectrometry. Total lipids were isolated using a 
modification to the Folch et al. (20) and Bligh and Dyer (21) methods. Briefly, cells were 
grown and supplemented with fatty acids using the short-term supplementation method 
indicated above, washed twice with 1X PBS, and then resuspended in 1 mL of 1X PBS 
containing 100µg mL-1 of lysozyme. Cells were incubated at 37°C for 20 minutes and then 
the lysozyme treated cells were transferred to a plastic screw top microfuge tube 
containing 0.5g of ≤106µm glass beads. Cells were subsequently homogenized using a 
mini-bead beater (Biospec Products, Bartlesville, OK) for two, one-minute intervals. 
Homogenized cells were transferred from the microfuge tube to a 15 mL polypropylene 
conical containing 2:1 (v/v) chloroform:methanol. After vortexing gently, the conical tubes 
were centrifuged for 5 minutes at 2739xG. The organic and inorganic phases were 
collected, leaving behind any debris and transferred to a new 15mL polypropylene conical 
containing 1.5 mL of 0.9% NaCl. After vortexing gently, the conical tubes were centrifuged 
for 5 minutes at 2739xG. Finally, the lower organic phase, containing extracted lipids, was 
collected and transferred to a glass screw top and evaporated using nitrogen gas. 
Ultra-Performance Liquid Chromatography High Resolution Mass Spectrometry 
(UPLC-HRMS). Lipid identification was performed in the manner of Tague et al 
(submitted). Lipid extracts (see above) were evaporated using nitrogen gas then 
suspended in 240 µL of 1:1 methanol: chloroform and 60µL of internal standard (IS) 
before being transferred to autosampler vials. Samples were stored in the autosampler 
at 4°C prior to analysis. An UltiMate 3000 ultra performance liquid chromatography 
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system (UPLC, Dionex, Sunnyvale, CA) was used to inject 10µL of sample onto a Kinetex 
HILIC column (100 Å, 2.6µm, 150mm x 2.1mm; Phenomenex, Torrance, CA) controlled 
at 35°C. Mobile phase A was 100% water with 5 mM ammonium acetate adjusted to pH 
5.8, and mobile phase B was 97:3 acetonitrile: water with 5mM ammonium acetate 
adjusted to pH 5.8. The gradient started at 97%B for 1 min, decreased to 95%B from 1.0-
1.2 min, held constant at 95%B from 1.2-4.0 min, decreased to 90%B from 4.0-4.2 
minutes, held constant at 90% from 4.2-7.6 min, decreased to 70%B from 7.6-8.1 min, 
held constant at 70%B from 8.1-10.9 min, decreased to 50%B from 10.9-11.0 min, and 
held constant at 50%B from 11.0-18.0 min. The flow rate for the separation was held 
constant at 200µL/min. The column was re-equilibrated for 12 minutes at 500µL/min.  
Eluent was introduced to the mass spectrometer via an electrospray ionization (ESI) 
source, with the following parameters: sheath gas 30 (arbitrary units), aux gas 8 (arbitrary 
units), sweep gas 3 (arbitrary units), spray voltage 3 kV, capillary temperature 300°C. 
Mass analysis was performed using a Q Exactive Plus (Thermo Scientific, Waltham, 
MA) mass spectrometer operated in parallel reaction mode (PRM). All ions were targeted 
in negative mode at a resolution of 140,000, automatic gain control (AGC) of 3x106 ions, 
maximum IT time was 100 ms, isolation window was 0.6 m/z, and the normalized collision 
energy was 35 eV. The mass spectrometer was calibrated every 24 hours with a negative 
mode calibration solution. 
UPLC-HRMS Standards and Calibration curves. Quantification of lipid species was 
performed in the manner of Tague et al (submitted).  All standards were purchased from 
Avanti Polar Lipids, Inc, and diluted in 9:1 methanol: chloroform for calibration curves. A 
standard from each of three classes of phospholipids was run to determine retention time 
and fragmentation. A non-natural internal standard (IS) was incorporated into the 
standards and biological samples at a final concentration of 8.3µM. Details of each 
standard are showed in Supplemental Table 4.4. The dehydrated glycerol-3-phosphate 
ion (m/z 152.9958) was used for quantification of all cardiolipin (CL) and 
phosphatidylglycerol (PG) compounds and a lysine fragment (m/z 145.0945) was used 
for lysyl-phosphatidylglycerol (L-PG) species. CL was targeted as the [M+2]2-while PG 
and L-PG was targeted as [M-1]1-. Standards were run in replicates of 6, before and after 
biological samples, ranging in concentration from 1nM to 50 uM, and the lower limit of 
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detection was 500nM for the CL and PGs and 50nM for L-PGs. Calibration plots were 
made by a log transformation of the ratio integration of the analyte to the internal standard 
against the log of ratio of the concentration of the analyte to the internal standard. 
UPLC-HRMS Targeted Compounds. A list of potential targeted lipids was created from 
previous FAME data showing which tail lengths are present in the biological system (8, 
9, 11). With this targeted list (Supplemental Table 4.3), we were able to quantify the lipids 
based on the common head group fragment, and subsequently extract the relative 
abundance of acyl tails from the PRM data. This allowed for an additional level of 
confirmation for the assigned peaks as well as being able to determine which tails are 
incorporated into each phospholipid. PG m/z were scanned from 0-4 minutes, CL m/z 
from 0-8 minutes and L-PG m/z 8-15 minutes. Xcalibur software from Thermo Scientific 
was used integrate areas under curve within a 5ppm widow of the exact fragment mass. 
Concentrations of all compounds within each head group class were calculated based on 
the calibration plot for the group’s external standard. Quantitated values were normalized 
to the optical density (OD600 nm) of the culture at the time of extraction. If values were 
below the limit of quantitation for more than three of five biological replicates, that 
phospholipid species was eliminated from the analysis and not accounted for in the 
averages of the phospholipid species. 
Statistical analysis. Differences in the membrane fatty acid content between growth 
conditions as well as differences in log ratio of survivors over time were determined using 
a two-tailed, unpaired Student’s t test. 
Results 
Supplementation with host fatty acids increases abundance of lysyl-
phosphatidylglycerol in the membrane of E. faecalis OG1RF. We previously showed 
that E. faecalis OG1RF can incorporate exogenous fatty acids from host fluids like bile 
and sera (8, 9). Additionally, short-term supplementation with oleic acid or linoleic acid, 
which are found in bile and sera, protected OG1RF from daptomycin (9). One possible 
explanation for these data is that incorporation of host fatty acids altered the phospholipid 
composition, leading to daptomycin tolerance (12, 13). To test this, we first isolated total 
lipids from E. faecalis OG1RF after short-term supplementation with either oleic acid, 
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linoleic acid, or solvent control and analyzed the composition of the cell membrane using 
targeted mass spectrometry (see Materials and Methods). We specifically quantified 
species of phosphatidylglycerol (PG), cardiolipin (CL) and lysyl-phosphatidylglycerol (L-
PG), the three major lipid classes identified in previous studies (12, 22, 23) and targeted 
individual lipid species based upon known fatty acid tail content (see Supplemental Table 
4.1) (8, 9, 11). Additionally, given the challenges of quantification of the CL class of 
species (24, 22, 25–27), we employed internal and external calibration curves. 
Following supplementation with oleic acid or linoleic acid, there was an overall 
reduction in the abundance of targeted PG species (from 57.4% to 22.1% in oleic acid 
and 20.4% in linoleic acid) and an increase in the abundance of targeted L-PG species 
(from 17.1% to 73.3% for both fatty acid supplements). Moreover, the abundance of CL 
was lower after supplementation with oleic acid or linoleic acid (from 25.5% to 4.7% in 
oleic acid and 6.4% in linoleic acid). Consequently, these trends were driven by specific 
species (Table 4.1). In the solvent control samples, the dominant PG species was PG 
34:1 (22.3 µM) followed by PG 32:1 (5.32 µM) and PG 36:2 (5.34 µM). These species 
were also the most dominant in the oleic acid and linoleic acid (exception PG 36:2) 
supplemented cells. The primary cardiolipin species was CL 72:0 and after 
supplementation with oleic acid and linoleic acid, we saw a reduction in this species from 
14.1 µM to 1.02 µM and 3.23 µM respectively. Surprisingly, we observed that every 
targeted L-PG species was increased after supplementation with oleic acid (73.3% of 
targeted L-PG) and linoleic acid (73.2% of targeted L-PG) relative to the solvent control 
(17.1% of targeted L-PG). 
 Given these findings, we hypothesized that increased tolerance after host fatty acid 
supplementation was due to increased L-PG. To test this hypothesis, we deleted mprF2 
(∆OG1RF_RS03930 – mprF2), which is responsible for transferring a lysine from lysyl-
tRNA to PG in E. faecalis (16).  
 
Deletion of mprF2 alters total membrane lipid content upon fatty acid 
supplementation. After supplementing parental OG1RF and ∆mprF2 strains with oleic 
acid or linoleic acid, we observed no differences in generation time (Supplemental Table 
4.5) or in the ability to incorporate exogenous fatty acids after short-term fatty acid 
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Table 4.1. E. faecalis OG1RF phospholipid composition during 
exponential-phase growth after short-term supplementation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PG – phosphatidylglycerol, CL – cardiolipin, L-PG – lysyl-phosphatidylglycerol 
BHI medium was used for all cultures 
aEthanol was used at a final concentration of 0.1% 
bOleic acid was used at a final concentration of 20 µg mL-1 
cLinoleic acid was used at a final concentration of 10 µg mL-1 
 
 µM concentrations of phospholipid 
species (Avg. ± SD) 
 OG1RF OG1RF OG1RF 
Phospholipid Ethanola Oleic acidb Linoleic acidc 
PG 32:0 1.83±0.62 0.96±0.31 0.97±0.24 
PG 32:1 5.32±1.31 1.97±0.58 1.67±0.25 
PG 34:0 2.29±0.69 0.93±0.20 0.91±0.15 
PG 34:1 22.3±3.95 9.83±2.35 8.13±1.64 
PG 34:2 2.17±0.55 1.14±0.32 1.11±0.11 
PG 36:0    
PG 36:1 1.78±0.60   
PG 36:2 5.34±2.1 1.33±0.50 0.78±0.10 
PG 36:3    
PG 36:4    
CL 56:0    
CL 64:0    
CL 64:1    
CL 64:2 0.74±0.19   
CL 66:0    
CL 66:1    
CL 68:0 0.87±0.10 0.74±0.20  
CL 68:1    
CL 70:0 1.42±0.42 1.65±0.30 1.02±0.41 
CL 70:1    
CL 70:3    
CL 70:4    
CL 72:0 14.1±3.74 1.02±0.22 3.23±0.64 
CL 72:1    
CL 72:2 1.13±0.13   
CL 72:3    
CL 72:4    
CL 72:8    
L-PG 32:0 0.54±0.10 3.11±0.90 3.47±0.61 
L-PG 32:1 1.04±0.29 7.83±2.35 5.24±0.71 
L-PG 34:0 0.74±0.14 2.95±1.00 3.66±0.67 
L-PG 34:1 7.09±1.11 28.9±9.36 24.3±4.51 
L-PG 34:2 0.72±0.23 2.79±0.99 5.61±0.98 
L-PG 36:0  0.13±0.06 0.12±0.03 
L-PG 36:1 0.54±0.13 1.08±0.42 1.26±0.27 
L-PG 36:2 1.45±0.16 6.71±2.98 3.24±0.36 
L-PG 36:3   1.10±0.17 
L-PG 36:4 0.09±0.02 0.20±0.11 0.81±0.19 
 
%PG 57.4 22 20.4 
%CL 25.5 4.7 6.4 
%L-PG 17.1 73.3 73.2 
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supplementation (Supplemental Table 4.6). To confirm that the ∆mprF2 strain was null 
for L-PG, we again conducted targeted mass spectrometry on both the parental strain 
and the ∆mprF2 strain. As expected, L-PG levels were below the limits of detection in 
∆mprF2 with the exception of L-PG 32:0 (Table 4.2). Overall, the parental strain and the 
∆mprF2 strain are dominated by the targeted PG species (85.8% of total and 90.2% of 
total, respectively), but that the ∆mprF2 phospholipid profile has decreased levels of PG 
32:1, 34:0, and 34:1 compared to the parental strain after ethanol supplementation. 
Targeted CL species were similar in these strains (7.9% of total and 9.8% of total, 
respectively) with CL 72:0 being the dominant cardiolipin species in both strains.  
After supplementation with host fatty acids, we observed an overall decrease in all 
targeted PG and CL species in ∆mprF2, which was similar to the parental strain (except 
CL 70:3). After oleic acid supplementation, the targeted PG species in the ∆mprF2 strain 
went from 90.2% of the total to 77.5% of the total, while the targeted CL species went 
from 9.8% of total to 27.5% of total. Similar trends were observed after linoleic 
supplementation of the ∆mprF2 strain (see Discussion). 
 
Short-term supplementation with oleic acid and linoleic acid increases tolerance to 
daptomycin but not SDS in a ∆mprF2 strain. After confirming the loss of detectable 
levels of L-PG in the ∆mprF2 strain, we wanted to conclude whether mprF2, and 
consequently L-PG, is responsible for the induction of membrane stress tolerance by host 
fatty acids. We first evaluated sensitivity to SDS and noted that overall basal tolerance to 
the detergent was greater than that in the parental strain (Supplemental Figure 4.1). 
However, supplementation with oleic acid (Supplemental Figure 4.1A) or linoleic acid 
(Supplemental Figure 4.1B) did not induce tolerance in either strain. Moreover, 
supplementation with linoleic acid seems to adversely impact the basal level tolerance to 
SDS (P £ 0.01). 
As supplementation with oleic acid or linoleic acid increased tolerance to daptomycin 
in OG1RF (9), we wanted to test if this observation would hold in the absence of L-PG. 
Interestingly, unlike what was noted for SDS sensitivity, the basal sensitivity to 
daptomycin was equivalent in the ∆mprF2 strain and parental strain. Furthermore, 
supplementation of ∆mprF2 with oleic acid (Figure 4.1A) or linoleic acid (Figure 4.1B) also  
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Table 4.2. E. faecalis OG1RF and E. faecalis ∆mprF2 phospholipid composition during 
exponential-phase growth after short-term supplementation. 
 
PG – phosphatidylglycerol, CL – cardiolipin, L-PG – lysyl-phosphatidylglycerol 
*Separate experiment 
BHI medium was used for all cultures. 
Ethanol was used at a final concentration of 0.1%. 
Oleic acid was used at a final concentration of 20 µg mL-1. 
Linoleic acid was used at a final concentration of 10 µg mL-1. 
 
 
 
104 
 
increased tolerance to daptomycin to a similar level as observed in the parental strain. 
These data suggest that the increased abundance of L-PG in the membrane was not 
responsible for increased tolerance to daptomycin.  
Given these data, we hypothesized that CL may contribute to membrane stress 
tolerance since altered levels of CL have been attributed to daptomycin tolerance (12, 
13). To test this, we deleted the two predicted genes responsible for cardiolipin synthesis, 
cardiolipin synthase 1 (∆OG1RF_RS01975 - ∆cls1) and cardiolipin synthase 2 
(∆OG1RF_RS06840 - ∆cls2).  
 
Supplementation with host fatty acids impacts growth of E. faecalis OG1RF lacking 
the two predicted cardiolipin synthase genes. We first wanted to assess how the loss 
of cardiolipin synthases might impact growth (Supplemental Table 4.5). The generation 
time in BHI and the solvent control, ethanol, was ~37 minutes for all strains. Upon 
supplementation with oleic acid, the parental and cardiolipin synthase deletion strains 
resulted in increased generation time (P = 0.0001). Further, the ∆cls1/cls2 strain was 
modestly impaired after oleic acid supplementation (~52 minutes, P = 0.0019), relative to 
the oleic acid supplemented parental strain. The generation times after supplementing 
parental, ∆cls1, and ∆cls2 strains with linoleic acid also greatly increased (~88 min, 78 
min, and 86 min respectively) versus the solvent control, which is consistent with previous 
observations (8). However, the ∆cls1/cls2 strain generation time was about three times 
greater after supplementation with linoleic acid (~253 min, P = 0.048) relative to the 
parental strain. Additionally, when mprF2 was deleted from the ∆cls1/cls2 strain 
generating a ∆mprF2/cls1/cls2 mutant, we still observed a significant impact to generation 
time (~195 min, P = 0.0014) versus the linoleic acid supplemented parental strain. 
Despite the impact to generation time in the ∆cls1/cls2 and ∆mprF2/cls1/cls2 strain 
after supplementation, these strains were not deficient in the uptake of exogenous fatty 
acid and the fatty acid composition is similar to previous observations with a wild-type 
strain of E. faecalis (Supplemental Table 4.6, 4.7, and 4.8) (9). 
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Figure 4.1. Host fatty acid supplementation protects mprF2 deficient Enterococcus 
faecalis from daptomycin challenge.  
OG1RF or OG1RF∆mprF2 was grown to mid log phase and then the culture was split 
and supplemented (see Materials and Methods). (A) Oleic acid supplementation and 
challenge with daptomycin. All strains supplemented with oleic acid had statistically 
increased numbers of survivors versus the solvent control at all time points analyzed (P 
= 0.002). (B) Linoleic acid supplementation and challenge with daptomycin. All strains 
supplemented with linoleic acid had statistically increased numbers of survivors versus 
the solvent control at all time points analyzed (P = 0.005). Shown are the averages ± 
standard deveiation for n = 3. 
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Deletion of the two predicted cardiolipin synthase genes results in a modified 
phospholipid profile after short-term supplementation with host fatty acids. To 
confirm a reduction in cardiolipin species in the ∆cls1/cls2 strain, we again performed 
targeted mass spectrometry. Surprisingly, we found that the mutant strain still produced 
CL. However, the ∆cls1/cls2 strain had a lower total percentage of CL species (15.4%) 
compared to the parental strain (25.5%), increased total percentage of PG (70.6% in the 
deletion versus 57.4% in the parent), and similar percent totals for L-PG species (14% 
versus 17.1% respectively) (Table 4.3).  
Previous reports have shown that as a cell transitions from exponential phase into 
stationary phase, the abundance of cardiolipin increases in the membrane (28–30). 
Consequently, we examined the cell membranes of parent and ∆cls1/cls2 strains (24-
hour growth normalized to OD600) to measure how the loss of OG1RF_RS01975 (∆cls1) 
and ∆OG1RF_RS06840 (∆cls2) impacted cardiolipin production at stationary phase. As 
shown in Table 4.4, percentage of total was reduced in the ∆cls1/cls2 strain (45% in 
parental and 21.9% in deletion strain), supportive of a role for these genes in stationary 
phase production of CL. When we analyzed the targeted CL species in the ∆cls1/cls2 
strain, there was a loss of several species that were present in the parental strain. 
Importantly, these data suggest that there is another, unidentified mechanism to generate 
cardiolipin that exists in OG1RF (see Discussion). 
In log phase cells, the parental and ∆cls1/cls2 strains supplemented with oleic acid 
resulted in similar trends in CL and L-PG but were quite disparate with respect to PG 
levels. In the ∆cls1/cls2 strain, we noted modest reductions in PG species (exception PG 
36:2), a 5-fold decrease in CL72:0, 2-fold increases in CL70:0, and overall increases in 
targeted L-PG species when compared to solvent control. In the parental strain, we noted 
a 2-fold reduction in PG species, a 14-fold decrease in CL72:0, and an overall increase 
in targeted L-PG species. 
Similar to oleic acid, we observed a disparity between the PG changes in parental 
and ∆cls1/cls2 strains after linoleic acid supplementation. In the ∆cls1/cls2 strain, we 
noted that some PG species levels stayed the same (PG 32:1, 34:0 34:1, 34:2), increased 
(PG 32:0), or decreased (PG 36:1, 36:2) when compared to the solvent control. 
Conversely, the parental strain showed 2-fold decreases in targeted PG species. In the  
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Table 4.3. E. faecalis OG1RF and OG1RF∆cls1/cls2 phospholipid composition during 
exponential-phase growth after short-term supplementation. 
 
PG – phosphatidylglycerol, CL – cardiolipin, L-PG – lysyl-phosphatidylglycerol 
BHI medium was used for all cultures 
Ethanol was used at a final concentration of 0.1% 
Oleic acid was used at a final concentration of 20 µg mL-1 
Linoleic acid was used at a final concentration of 10 µg mL-1 
 
108 
 
Table 4.4. E. faecalis OG1RF, ∆cls1/∆cls2, ∆cls1, and ∆cls2 phospholipid composition 
during stationary phase. 
 
PG – phosphatidylglycerol, CL – cardiolipin, L-PG – lysyl-phosphatidylglycerol 
BHI medium was used for all cultures 
Ethanol was used at a final concentration of 0.1% 
Oleic acid was used at a final concentration of 20 µg mL-1 
Linoleic acid was used at a final concentration of 10 µg mL-1 
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∆cls1/cls2 strain, the CL levels stayed consistent with the solvent control (exception 
CL72:0) and like the oleic acid supplemented samples, L-PG species increased after 
supplementation with linoleic acid. The parental strain showed decreases in CL and an 
overall increase in L-PG after linoleic acid supplementation. 
Taken together, these data demonstrate that despite the presence of cardiolipin in 
the membrane of the ∆cls1/cls2 strain, our targeted lipidomics analyses showed 
increased amounts of specific targeted PG and L-PG species after supplementation with 
oleic acid and linoleic acid.  
 
Supplementation of strains lacking the predicted cardiolipin synthase genes 
provide no protection against SDS induced membrane stress. Despite the presence 
of cardiolipin in the ∆cls1/cls2 strain, we observed an altered phospholipid profile 
compared to parental that could impair membrane stress tolerance. (8, 9). When the 
strains were challenged with SDS, we noted no difference in the single deletion strains 
(Supplemental Figure 4.2), but the ∆cls1/cls2 strain was more sensitive than the parental 
strain, implying that basal tolerance to SDS requires these two gene products (Figure 
4.2A). Nor did supplementation with oleic acid or linoleic acid alter this enhanced 
sensitivity to SDS (Supplemental Figure 4.3). 
Given this heightened sensitivity of the ∆cls1/cls2 to SDS, we extended the length 
of SDS challenge to 18 hours. As shown in Figure 4.2B, the parental strain did recover 
after 4 hours of treatment. Conversely, the ∆cls1/cls2 strain was unable to recover from 
SDS challenge. This lack of protection in the ∆cls1/cls2 mutant strain suggest that both 
predicted cardiolipin synthase enzymes are involved in extended basal sensitivity and 
that they are required for recovery from SDS challenge. Further, these data suggest that 
fatty acid supplementation does not facilitate recovery from SDS. 
 
Host fatty acids can induce daptomycin tolerance in OG1RF strains lacking cls1 
and cls2. Given the increased basal sensitivity to SDS, we examined daptomycin 
sensitivity to ∆cls1/cls2. We first noted, that the ∆cls1/cls2 strain had increased basal 
sensitivity to daptomycin (P = 0.002), while the ∆mprF2/cls1/cls2 strain did not (Figure 
4.3). Again, this is supportive of a role of cls1 and cls2 for membrane response, despite  
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Figure 4.2. Cardiolipin synthase double deletion strain has increased sensitivity to 
SDS challenge.  
(A) The ∆cls1/cls2 strain has increased sensitivity as compared to the parental OG1RF 
strain. (B) Extended challenge with SDS results in no detectable cells in the ∆cls1/cls2 
strain after 2 hours. Shown are the average ± standard deviation for n = 3. 
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having detectable levels of CL (see Discussion). As shown in Figure 4.3, the ∆cls1/cls2 
strain demonstrated increased tolerance to daptomycin after supplementation with oleic 
acid (Figure 4.3A) or linoleic acid (Figure 4.3B) similar to the parental and single deletion 
strains (Supplemental Figure 4.4A and 4.4B). Despite oleic acid and linoleic acid inducing 
tolerance within an hour of daptomycin treatment, after 4 hours of daptomycin exposure, 
there were no detectable cells (Figure 4.4). 
Combined, these data suggest that the two predicted cardiolipin synthases are critical 
for long term survival against daptomycin, but that supplementation with host fatty acids, 
which induce tolerance, is independent of mprF2, cls1, and cls2.  
Discussion 
Previous data from our lab showed that supplementation with specific host fatty acids, 
from host fluids, can increase tolerance to membrane stressors including daptomycin (8, 
9, 11). As there have been notable links to phospholipid content and distribution in 
daptomycin protection, we examined if phospholipid alterations may contribute to 
daptomycin tolerance (12, 13). Here, we demonstrated that oleic acid and linoleic acid 
supplementation leads to alterations in the proportion of specific phospholipid species, 
particularly L-PG in the membrane of E. faecalis. Studies have shown that L-PG, and 
other amino-modifications to PG are protective from cationic antimicrobial peptides (31). 
It is likely that within fatty acid rich host fluids, E. faecalis has a membrane composition 
that is primed for tolerance to host defenses, contributing to its stability in the host 
environment. However, as shown in this study, formation of L-PG via MprF2 is not needed 
to induce tolerance to daptomycin by host fatty acids. 
Other genetic data has implied a role for cardiolipin in daptomycin resistance, 
although it is not the primary reason for genetic resistance in E. faecalis. Genome 
sequencing of a daptomycin clinical strain pair demonstrated that a mutation in cls which 
encodes a cardiolipin biosynthetic enzyme is associated with resistance (6). However, 
removing a sensitive cls allele from one strain of E. faecium and exchanging it for a 
daptomycin resistant allele did not change daptomycin susceptibility (32). Conversely, in 
E. faecalis, expressing a mutated putative cardiolipin synthase allele in trans increased 
resistance to daptomycin in an otherwise daptomycin sensitive strain (7). Herein, we  
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Figure 4.3. Short-term fatty acid supplementation with host fatty acids protects 
cardiolipin synthase double deletion mutants from daptomycin challenge.  
(A) Oleic acid supplementation of ∆cls1/cls2 and ∆mprF2/cls1/cls2 had statistically 
increased numbers of survivors versus the solvent control at all time points (P <0.0001). 
(B) Linoleic acid supplementation of ∆cls1/cls2 and ∆mprF2/cls1/cls2 had statistically 
increased numbers of survivors versus the solvent control at all time points assessed (P 
= 0.0001). Shown are the average ± standard deviation for n = 3. 
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Figure 4.4. Short-term supplementation with oleic acid does not protect cardiolipin 
synthase double knock out strains from extended daptomycin challenge.  
Oleic acid supplementation and challenge with daptomycin. OG1RF supplemented with 
oleic acid shows delayed kinetics of killing. The cardiolipin synthase double mutant 
succumbs to extended daptomycin exposure. Shown are the average ± standard 
deviation for n = 3 
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showed that deletion of two predicted cardiolipin synthases surprisingly only impaired 
total CL levels in stationary phase. These two genes were critical for basal sensitivity to 
the membrane damaging agents, SDS and daptomycin, but, fatty acids can induce 
tolerance to daptomycin. This was also seen in a strain lacking mprF2/cls1/cls2. Could 
this increased basal sensitivity be explained by the increased presence of 
phosphatidylglycerol in the membrane? Studies using liposomes and Bacillus subtilis 
have shown that daptomycin preferentially inserts into phosphatidylglycerol rich areas 
(33–35). Given this, after supplementation with oleic acid and linoleic acid, we still see 
relatively high amounts of PG even though the percent total of this phospholipid is 
reduced. Alternatively (or perhaps both), oleic acid and linoleic acid induced specific gene 
expression and as a consequence, increases tolerance. Studies in Staphylococcus 
aureus have shown that supplementation with oleic acid can indeed impact gene 
expression especially those genes under the control of the SaeRS two-component 
system (36). Further work is needed to determine if the presence of oleic acid or linoleic 
is inducing transcriptional changes in E. faecalis. 
The results of this study concluded that tolerance was independent of mprF2, cls1, 
and cls2, however, several results were surprising. We chose in our analysis to measure 
quantitatively the major phospholipid species in E. faecalis OG1RF (PG, CL, and L-PG) 
using mass spectrometry and for CL species, we specifically targeted those specific 
phospholipid species that we believed would best represent the dominant fatty acid tails 
found in OG1RF in the presence or absence of host fatty acid supplementation (8, 9, 11). 
Consequently, we were unable to fully analyze the entire lipidome of OG1RF and there 
are phospholipid species that are not accounted for in our analysis (22, 37). However, the 
loss of L-PG does not cause an increase in targeted PG levels. These data infer that other 
phospholipid species may be accumulating. One possibility is that in the absence of L-
PG, OG1RF is producing other amino-containing PG species. This is unlikely, however, 
given the evidence that mprF2 can aminoacylate PG with other amino acids besides 
lysine (16). Alternatively, as L-PG is no longer formed, perhaps PG is now serving as a 
precursor of glycerophospho-diglucosyl-diacylglycerol or lipoteichoic acid constituents 
(38). Further analyses would be needed to determine these changes. 
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Another notable finding from this work is that despite deletion of the two predicted cls 
genes, the strain produced detectable levels of cardiolipin. Note that additional attempts 
to identify other cls genes using the characteristic HKD motif were unsuccessful (data not 
shown). Thus, there is an alternative mechanism for CL production in OG1RF. This result 
is not totally surprising given that CL is one of the major phospholipids in enterococcus. 
Moreover, studies have shown that cardiolipin plays a role in survival of E. coli as the cell 
enters stationary phase (28, 39), organizing the membrane, and cell division (40). Data 
have shown that species such as Escherichia coli have three Cls-isoenzymes that can 
produce CL. The purpose of having these three different enzymes to produce CL still 
remains unclear (41). However, there are several mechanisms that can make CL. One 
mechanism found in most bacteria, involves the condensation of two PG molecules. 
Another mechanism utilizes phosphatidylethanolamine (PE) and PG as substrates (42). 
Moreover, there is another cardiolipin synthesis mechanism that has been discovered in 
bacteria using a “eukaryotic-like” pathway where cytidine diphosphate-diacylglycerol 
(CDP-DAG) donates a phosphatidyl group to PG to form CL (43). As previously stated, 
given the number of mechanisms involved in the synthesis of CL, and a possible yet to 
be identified mechanisms, it is not surprising that we find CL in E. faecalis 
OG1RF∆cls1/cls2. However, despite the presence of cardiolipin, we observed 
subsequent increased basal sensitivity to daptomycin. 
Taken together, we found that after supplementation with host fatty acids, oleic acid 
and linoleic acid, the phospholipid profile changed. Despite an altered profile with the 
parental strain, deletion of mprF2, cls1, and cls2 still resulted in increased tolerance 
during early exposure to daptomycin. However, extended exposure to daptomycin in the 
cls double deletion strain elucidates a possible role of these genes in our observations. 
Thus, host fatty acid induced daptomycin tolerance during acute exposure to membrane 
stressors is through a yet to be determined pathway. 
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Supplemental Table 4.1. Stains and plasmids used in this study. 
Strain Relevant genotype or description Source 
Enterococcus faecalis OG1RF Lab strain  
Escherichia coli EC1000 Cloning strain for repA-dependent plasmids; 
repA on chromosome 
 
E. faecalis CK111/pCF10-101 Conjugative donor strain; repA on chromosome 
and harbors non-transferrable pCF10 derivative 
plasmid 
Kristich et al. (2007) Plasmid 
57(2) 131-144 
   
Plasmids   
pCJK47 Used for markerless exchange; requires RepA 
in trans. Contains: oriTpCF10, lacZ, and P-pheS. 
Kristich et al. (2007) Plasmid 
57(2) 131-144 
pJRH1 pCJK47 derivative containing flanking regions 
of OG1RF_RS01975 (cls1) 
This work 
pJRH2 pCJK47 derivative containing flanking regions 
of OG1RF_RS06840 (cls2) 
This work 
pMprF2 pCJK47 derivative containing flanking regions 
of OG1RF_RS03930 (mprF2) 
This work 
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Supplemental Table 4.2. Oligonucleotides used in this study. 
Name Sequence Use 
Oligonucleotides used for splicing by overlap extension (SOE)1 to generate inserts 
EF1097 GTCCAAGGATTCTCACCATTGATGCAAGGCC Isolate DNA upstream of cls1 (cls1A) 
EF1098 CTGGAGTCATTGTTGTACTATACCATCAATTACGGATTTGGAATATC Isolate DNA upstream of cls1 (cls1B) 
EF1099 CGTAATTGATGGTATACGTACAACAATGACTCCAGAAGTTGTTCGTGAC Isolate DNA downstream of cls1 (cls1C) 
EF1105 GACTGTCCATGGTATGTTGCACAGCTTCCATCG Isolate DNA downstream of cls1 (cls1D) 
EF1103 CAAGACTGGTGACCAACGTCATCATCCATGCTAAAACGCTGG Isolate DNA upstream of cls2 (cls2C) 
EF1108 CCCAAGCCCGGGCGATTGACCAGGACCACTTAAAACTCC Isolate DNA upstream of cls2 (cls2D) 
EF1113 GGTCACGGATTCTCCAAACAAGGTAACC Isolate DNA downstream of cls2 (cls2A) 
EF1102 CATGGATGATGACGTTGGTCACCAGTCTTGTAATCAATAAATCAGCAGTG Isolate DNA downstream of cls2 (cls2B) 
   
Oligonucleotides used for Gibson assembly 
EF1449 CAATCACTAGTGAATTCGCGGCCGCCACGGCGATATCGG Generate overhangs on pCJK47 for cls1 
EF1450 CAATCGAATTCCCGCGGCCGCTCTAGAACTAGCGATTCTGAAATCAC Generate overhangs on pCJK47 for cls1 
EF1451 CAGAATCGCTAGTTCTAGAGCGGCCGCGGGAATTCGATTGT Generate overhangs on cls1 insert 
EF1452 CATATGGATCCGATATCGCCGTGGCGGCCGCGAATTCACTAGTGATTGACTG Generate overhangs on cls1 insert 
EF1453 GGGAATCACTAGTGAATTCGCGGCCGCACGGCGATATCGGATCC Generate overhangs on pCJK47 for cls2 
EF1454 CCGTGACCAATCGAATTCCCGCGGCCGCTCTAGAACTAGCGATTCTGAAATCAC Generate overhangs on pCJK47 for cls2 
EF1455 CAGAATCGCTAGTTCTAGAGCGGCCGCGGGAATTCGATTGG Generate overhangs on cls2 insert 
EF1456 CATATGGATCCGATATCGCCGTGCGGCCGCGAATTCACTAGTGATTCCCAAG Generate overhangs on cls2 insert 
EF1601 GACAAAACCCCTAATAATTCTTTTGCTTCATCCATGCCCGGGTACCATGGCATGC
TAAGCTTGATTTTCGTTC 
Generate overhangs on pCJK47 for mprF2 
EF1602 CTTTTGATCAAAAACAGGATTTTCTCTAGAACTAGCGATTCTGAAATCACCATTT
AAAAAACTC 
Generate overhangs on pCJK47 for mprF2 
EF1603 GAGTTTTTTAAATGGTGATTTCAGAATCGCTAGTTCTAGAGAAAATCCTGTTTTT
GATCAAAAG 
Generate overhangs on DNA upstream of mprF2 
EF1604 CAATCCAGCTACTTTTAGAATAAAGTGTATAGCAACAACAATAATTGAGACCGCA
ATAACAAAC 
Generate overhangs on DNA upstream of mprF2 
EF1605 GTTTGTTATTGCGGTCTCAATTATTGTTGTTGCTATACACTTTATTCTAAAAGTA
GCTGGATTG 
Generate overhangs on DNA downstream of mprF2 
EF1606 GAACGAAAATCAAGCTTAGCATGCCATGGTACCCGGGCATGGATGAAGCAAAAGA
ATTATTAGGGGTTTTGTC 
Generate overhangs on DNA downstream of mprF2 
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Supplemental Table 4.3. List of targeted phospholipid 
species. 
Phosphatidylglycerol Cardiolipin Lysyl-phosphatidylglycerol 
PG 16:0 CL 56:0 L-PG 32:0 
PG 32:0 CL 64:0 L-PG 32:1 
PG 32:1 CL 64:1 L-PG 34:0 
PG 34:0 CL 64:2 L-PG 34:1 
PG 34:1 CL 66:0 L-PG 34:2 
PG 34:2 CL 66:1 L-PG 36:0 
PG 36:0 CL 68:0 L-PG 36:1 
PG 36:1 CL 68:1 L-PG 36:2 
PG 36:2 CL 70:0 L-PG 36:3 
 CL 70:1 L-PG 36:4 
 CL 70:3  
 CL 70:4  
 CL 72:0  
 CL 72:1  
 CL 72:2  
 CL 72:3  
 CL 72:4  
 CL 72:8  
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Supplemental Table 4.4. Standards used for targeted mass spectrometry. 
Compound Class Tails Abbreviation Standard Type 
Cardiolipin 4-C18:1  CL (72:4) External Standard 
Cardiolipin 4-C14:0 CL (54:0) Internal standard 
Phosphatidylglycerol 2-C18:0 PG (36:0) External Standard 
Phosphatidylglycerol 2-C8:0 PG (16:0) Internal standard 
Lysyl-phosphatidylglycerol 2-C18:1 LPG (36:1) External Standard 
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BHI medium was used for all cultures. 
aEthanol was used at a final concentration of 0.1%. 
bOleic acid was used at a final concentration of 20 µg mL-1. 
cLinoleic acid was used at a final concentration of 10 µg mL-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 4.5. Exponential phase generation times. 
 Generation times in medium constituent (min) 
Strain Ethanola Oleic acidb Linoleic acidc 
OG1RF 37.0 ± 0.3 47.0 ± 1.1 88.2 ± 8.3 
∆mprF2 38.3 ± 1.0 36.2 ± 1.5 74.8 ± 6.9 
∆cls1 36.7 ± 1.5 47.2 ± 0.2 77.5 ± 1.1 
∆cls2 35.9 ± 1.0 50.1 ± 2.3 86.0. ± 6.8 
∆cls1/cls2 35.0 ± 0.9 52.2 ± 0.4 252.9 ± 98.5 
∆mprF2/cls1/cls2 38.8 ± 5.1 39.7 ± 3.5 195.5 ± 22.2 
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Supplemental Table 4.6. E. faecalis OG1RF and ∆mprF2 membrane fatty acid 
composition during exponential-phase growth. 
 % of total membrane content (Avg. ± SD) 
 Ethanola Oleic acidb - C18:1 cis 9 Linoleic acidc - C18:2 cis 9,12 
Fatty acid OG1RF ∆mprF2 OG1RF ∆mprF2 OG1RF ∆mprF2 
C12:0 1.8 ± 0.3 1.2 ± 0.1 0.7 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.4 ± 0.2 
C14:0 4.8 ± 0.1 4.6 ± 0.2 2.5 ± 0.2 4.2 ± 0.1 3.7 ± 0.1 4.3 ± 0.4 
C16:1 cis 9 7.2 ± 0.1 6.6 ± 0.3 3.8 ± 0.3 5.7 ± 0.3 6.1 ± 0.04 5.9 ± 0.2 
C16:0 37.8 ± 0.4 38.6 ± 0.4 19.5 ± 0.6 31.1 ± 0.1 29.6 ± 0.5 31.0 ± 2.1 
C18:1 cis 9 1.7 ± 0.2 ND 46.7 ± 1.7 11.1 ± 1.0 ND ND 
C18:1 cis 11 38.3 ± 0.5 39.6 ± 0.1 19.0 ± 0.6 29.9 ± 0.3 28.6 ± 0.5 26.6 ± 1.7 
C18:0 5.0 ± 0.1 5.5 ± 0.2 2.9 ± 0.2 3.8 ± 0.2 4.3 ± 0.1 4.2 ± 0.5 
C18:2 cis 9,12 ND ND ND ND 24.0 ± 0.9 23.4 ± 3.1 
C17:0 2OH 2.0 ± 0.2 2.8 ± 0.4 1.1 ± 0.1 1.8 ± 0.3 1.6 ± 0.1 1.9 ± 0.2 
C19:0 cyclo 11 ND 0.8 ± 0.0 ND 0.8 ± 0.1 ND 0.7 ± 0.1 
C20:0 ND ND 3.2 ± 0.3 10.0 ± 1.0 ND ND 
Otherd 1.3 ± 0.6 0.4 ± 0.7 0.6 ± 0.2 0.5 ± 0.5 0.9 ± 0.3 0.7 ± 1.0 
Sat/Unsat 1.1 ± 0.02 1.2 ± 0.04 0.4 ± 0.5 1.1 ± 0.1 0.7 ± 0.5 0.8 ± 0.6 
C10 - C17 / 
C18 - C20e 
1.2 ± 0.01 1.2 ± 0.01 0.4 ± 0.4 0.8 ± 0.02 0.7 ± 0.5 0.8 ± 0.6 
 
Membrane contents were determined using GC-FAME analysis by Microbial ID, Inc.; 
numbers represent average ± standard deviation from three independent cultures.; ND 
indicates that fatty acid was not detected. 
aEthanol was added at a final concentration of 0.1%. 
bOleic acid was added at a final concentration of 20 µg mL-1. 
cLinoleic acid was added at a final concentration of 10 µg mL-1. 
dOther indicates fatty acids that comprised <1% of the total membrane content. 
eFatty acid length ratio includes both saturated and unsaturated fatty acid. 
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Supplemental Figure 4.1. Short-term fatty acid supplementation with host fatty 
acids does not protect OG1RF∆mprF2 from SDS challenge.  
The ∆mprF2 strain has decreased sensitivity as compared to the parental OG1RF strain. 
(A). Supplementation of ∆mprF2 with oleic acid does not increase protection against SDS 
challenge. (B) Supplementation of ∆mprF2 with linoleic acid does not increase protection 
against SDS challenge. Shown are the average ± standard deviation for n = 3. 
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Supplemental Table 4.7. E. faecalis OG1RF parental, ∆cls1, and ∆cls2 membrane fatty acid 
composition during exponential-phase growth. 
 
 
Membrane contents were determined using GC-FAME analysis by Microbial ID, Inc.; numbers represent 
average ± standard deviation from three independent cultures.; ND indicates that fatty acid was not 
detected. 
aEthanol was added at a final concentration of 0.1%. 
bOleic acid was added at a final concentration of 20 µg mL-1. 
cLinoleic acid was added at a final concentration of 10 µg mL-1. 
dOther indicates fatty acids that comprised <1% of the total membrane content. 
eFatty acid length ratio includes both saturated and unsaturated fatty acid. 
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Supplemental Table 4.8. E. faecalis OG1RF parental, ∆cls1/ cls2, and ∆mprF2/ cls1/ cls2 membrane fatty acid composition during 
exponential-phase growth. 
 
 
Membrane contents were determined using GC-FAME analysis by Microbial ID, Inc.; numbers represent average ± standard deviation from three 
independent cultures.; ND indicates that fatty acid was not detected. 
aEthanol was added at a final concentration of 0.1%. 
bOleic acid was added at a final concentration of 20 µg mL-1. 
cLinoleic acid was added at a final concentration of 10 µg mL-1. 
dOther indicates fatty acids that comprised <1% of the total membrane content. 
eFatty acid length ratio includes both saturated and unsaturated fatty acid. 
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Supplemental Table 4.9. E. faecalis OG1RF, ∆cls1, and ∆cls2 phospholipid composition 
during exponential-phase growth after short-term supplementation. 
 
 
PG – phosphatidylglycerol, CL – cardiolipin, L-PG – lysyl-phosphatidylglycerol 
BHI medium was used for all cultures. 
aEthanol was used at a final concentration of 0.1%. 
bOleic acid was used at a final concentration of 20 µg mL-1. 
cLinoleic acid was used at a final concentration of 10 µg mL-1. 
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Supplemental Figure 4.2. Short-term fatty acid supplementation with host fatty 
acids does not protect OG1RF∆cls1 or ∆cls2 from SDS challenge.  
(A). Supplementation of ∆cls1 or ∆cls2 with oleic acid does not increase protection against 
SDS challenge. (B) Supplementation of ∆cls1 or ∆cls2 with linoleic acid does not increase 
protection against SDS challenge. Shown are the average ± standard deviation for n = 3. 
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Supplemental Figure 4.3. Increased sensitivity to SDS in the cardiolipin synthase 
double deletion strain. 
(A) Oleic acid supplementation and challenge with SDS. The parental strain (OG1RF) 
supplemented with oleic acid was similar to the ethanol control. The cardiolipin synthase 
double mutant strains had increased sensitivity to SDS (P = 0.0006) and no increased 
tolerance after oleic acid supplementation. (B) Linoleic acid supplementation and 
challenge with SDS. Each strain supplemented with linoleic acid was similar to the solvent 
control. At time 60, the cardiolipin synthase mutant was more sensitive to SDS as 
compared to the parent strain (P = 0.002). Shown are the average ± standard deviation 
for n = 3. 
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Supplemental Figure 4.4. Short-term fatty acid supplementation with host fatty 
acids protects OG1RF∆cls1 or OG1RF∆cls2 from daptomycin challenge.  
(A) Oleic acid supplementation of ∆cls1 or ∆cls2 statistically increased numbers of 
survivors versus the solvent control at all time points (P <0.0001). (B) Linoleic acid 
supplementation of ∆cls1 or ∆cls2 had statistically increased numbers of survivors versus 
the solvent control at all time points assessed (P = 0.0001). Shown are the average ± 
standard deviation for n = 3. 
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CHAPTER V: Conclusions and future direction 
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Previous data from our lab found that growth of E. faecalis with host fluids, such as bile 
(GI tract) or serum (wounds), provided fatty acids which can be incorporated into the 
membrane of E. faecalis and result in increased tolerance to membrane damaging agents 
(1, 2). Further work showed that E. faecalis responds uniquely to each fatty acid 
supplement and that of those examined only oleic acid and linoleic acid increase 
tolerance to membrane damaging agents (2). The studies presented in this dissertation 
were designed to elucidate why the eukaryotic host fatty acids, oleic acid and linoleic acid, 
increase tolerance to membrane damaging agents in the hospital-acquired pathogen 
Enterococcus faecalis. 
 
Fatty acid analogs to understand fatty acid induced daptomycin tolerance 
Oleic acid and linoleic acid are similar in that they contain fatty acid tails consisting of 18 
carbons and are unsaturated with the bond(s) in the cis position. However, supplementing 
with fatty acids containing 18 carbons does not confer tolerance because stearic acid 
(C18:0) and cis-vaccenic acid (C18:1 cis 11) do not rescue (1, 2). I designed experiments to 
better discern how the cell may respond “positively” to oleic acid or linoleic acid, whereas 
similar fatty acids do not promote tolerance. My experiments found that the cis bond was 
important for daptomycin tolerance but increasing the number of unsaturated cis bonds 
was not (Figure 2.1). The most critical finding from this analysis was that oleic acid and 
linoleic acid need the carboxyl group to induce tolerance, as was demonstrated by using 
analogs containing an amide group instead of a carboxyl group (Figure 2.3). Lipidomic 
analysis demonstrates that the loss of the carboxyl group prevents phospholipid 
incorporation and supports the hypothesis that incorporation into a head group is an 
important step in triggering tolerance (Figure 2.4).  This is further supported by published 
work in S. aureus (3). 
 
Fatty acid induced membrane stress responses 
To assess whether or not protective fatty acids increase tolerance to membrane 
damaging agents by triggering a membrane stress response, I used a daptomycin 
hypersusceptible mutant strain of OG1RF that lacks liaR of the LiaFSR three component 
system (4). LiaFSR consists of a membrane bound sensor histidine kinase (LiaS), a 
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negative regulator (LiaF), and response regulator (LiaR) and has been shown to be 
important for responses to cell envelope targeting antibiotics and antimicrobial peptides 
(5) including daptomycin (6). By using a strain that is deficient in liaR, we discovered that 
supplementing with oleic acid increased tolerance to daptomycin (7) and suggests that 
the LiaFSR pathway is not involved in our observations. However, these data could not 
eliminate the possibility that another membrane sensing mechanism is involved in our 
observations. 
To address the possibility that another membrane stress response system is 
involved, we collaborated with Dr. Chris Kristich at the Medical College of Wisconsin. The 
Kristich laboratory tested to see if two cell envelope stress sensing two component 
systems, CroSR and IreK, might be responding to the addition of oleic acid (data not 
shown). CroSR is normally involved in cell wall stress responses and was found to elicit 
cell wall repair upon stimulation. In the absence of CroR, cells are more sensitive to cell 
wall targeting antibiotics, such as vancomycin (8). Further, IreK has been shown to be 
involved in cell wall homeostasis (9). By assessing these two potential stress response 
pathways we could test the possibility that host fatty acids might be triggering a response. 
We found that they were not. However, these results again do not mean that 
supplementation with host fatty acids are not having an impact on other cell stress/two-
component systems.  
Perturbations in cell envelope homeostasis can trigger a stress response (10) and 
modifying the normal composition of acyl tails could indeed have an effect. Further, 
unsaturated fatty acids can impact the lateral pressure within the membrane bilayer, 
which can subsequently impact the activity of proteins embedded in the membrane (11). 
Also, the position of the double bond within the fatty acid tail can also impact the 
membrane. Data shows that a fatty acid with a double bond at the geometric center of the 
molecule has the lowest phase transition temperature (12), can increase the overall 
surface area of the membrane, cause thinning of the membrane, and cause the acyl 
chains to be more disordered (13). Each of these biophysical changes that occur with 
unsaturated fatty acids might be causing downstream effects that influence not only 
membrane signaling proteins, but overall cellular metabolic processes, which could then 
impact gene expression. Given this, rather than targeting each stress response 
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mechanisms specifically at first, I want to test how the transcriptome of OG1RF changes 
upon addition of host fatty acids. To test the hypothesis that protective host fatty acids 
are triggering a membrane stress response or influencing other changes, RNA 
sequencing will be conducted.  
 
Unexplored phospholipid alterations could contribute to membrane stress 
tolerance. 
We conducted targeted mass spectrometry to conclude if supplementation with oleic acid 
or linoleic acid alters the phospholipid profile, and thereby increases protection. We 
observed that supplementation with oleic acid and linoleic acid increased the amount of 
lysyl-phosphatidylglycerol (L-PG) and reduced the level of cardiolipin (CL) (Table 4.1). To 
conclude if these alterations contributed to host fatty acid induced tolerance, we deleted 
the predicted genes responsible for lysyl-phosphatidylglycerol synthesis (mprF2) and 
cardiolipin synthesis (cls1 and cls2), which resulted in loss of L-PG and a reduction of CL 
respectively (Table 4.2 and Table 4.3). However, supplementation of these strains with 
oleic acid and linoleic acid still resulted in increased tolerance to daptomycin during the 
first 60 minutes of challenge (Figure 4.1 and Figure 4.3). These data suggested that 
supplementation with oleic acid or linoleic acid alter the levels of L-PG and CL, but the 
altered levels are not responsible for increased membrane tolerance during the early 
exposure to membrane stressors.  
Previous studies have shown that there are a number of membrane changes that can 
impact daptomycin sensitivity. Studies using E. faecalis clinical isolates or evolved strains 
and liposome models have identified causes of reduced daptomycin sensitivity including: 
decreased amounts of PG, increased amounts of CL, altered localization of CL, deletion 
of LiaR of the LiaFSR stress response systems, and increased amounts of 
glycerophospho-diglycodiacylglycerol (GD-DGDAG) (14). As stated above, we have 
investigated changes to the phospholipid profile, but we have not investigated all of the 
phospholipid species that may be changing after supplementation. One species of 
phospholipid that may be increasing as a consequence of host fatty acid supplementation 
is GD-DGDAG (Figure 5.1). Analysis of a daptomycin resistant strain of E. faecalis found 
that there was nearly a two-fold increase in the amount of GD-DGDAG in the membrane 
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(14, 15). Following up on this particular lipid species could be important because it has 
been shown that glycolipids are involved in the synthesis of lipotechoic acids (LTA), which 
are important for cation homeostasis, antimicrobial peptide resistance, and biofilm 
formation (16–18). If the incorporation of host fatty acids promotes glycolipid production, 
this might increase LTA production, which could increase tolerance to membrane 
stressors. An approach to address this hypothesis could involve generating a ∆bgsB (a 
glycosyltransferase responsible for synthesizing monoglucosyldiacylglycerol) strain and 
testing if oleic acid or linoleic acid supplementation can still induce daptomycin tolerance.  
 
Location of supplemented fatty acids in the phospholipid profile 
An unresolved question we have had since the beginning of this work is where do host 
fatty acids go when they are incorporated into the membrane of E. faecalis? We have 
mass spectrometry data showing that free fatty acids can be found in the membrane, and 
we can also infer based on m/z that after supplementation with host fatty acids, we see 
an increase in L-PG (34:1, 34:2, or 36:2) species that could contain the supplemented 
fatty acid. However, ascertaining specific details regarding the localization of 
supplemented fatty acids within phospholipids has not been conducted with confidence. 
In bacteria, the current hypothesis is that exogenous fatty acids are incorporated into the 
sn1 and sn2 positions of glycerol-3-phosphate using fatty acid kinase and then shuttled 
through phospholipid synthesis (19) Further, there is very little evidence that bacteria can 
remodel their membrane phospholipids (20, 21). However, in the yeast model organism, 
Saccharomyces cerevisiae, it is known that a post-synthetic process can occur to replace 
one or both acyl chains in a phospholipid (22). 
In an effort to specifically identify the localization of supplemented fatty acids, we 
used 14C-containing oleic acid to understand where the supplemented fatty acid was 
going in the phospholipid profile. In this radiolabeled fatty acid tracking experiment using 
extracted phospholipids and one-dimensional thin layer chromatography (TLC), we 
observed a rapid increase in localization of this radiolabeled fatty acid into cardiolipin and 
then a subsequent localization to phosphatidylglycerol (Figure 5.2). These preliminary 
data were quite interesting and made me hypothesize that E. faecalis is exchanging the 
acyl tails on cardiolipin instead of adding the exogenous fatty acids onto newly  
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Figure 5.1 Phospholipid synthesis and lipoteichoic acid precursor synthesis in E. 
faecalis and the predicted enzymes involved.  
After production of phosphatidylglycerol, enterococcus can synthesize precursors for 
lipoteichoic acid or recycle phosphatidic acid. cdsA, cytidine diphosphate synthase; pgs, 
phosphatidylglycerol-phosphate synthase; pgp, phosphatidylgycerol phosphate 
phosphatase; ltaS, lipoteichoic acid synthase; bgsB and bgsA, glycosyltransferase; dgk, 
diacylglycerol kinase. 
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Figure 5.2 Extracted lipids from log phase E. faecalis OG1RF after supplementation 
with radiolabeled oleic acid shows quick incorporation into cardiolipin using thin 
layer chromatography.  
(Top) Primulin stained lipids shows location of cardiolipin and phosphatidylglycerol 
standards and increased abundance of CL after supplementation with fatty acid. (Middle) 
30 minutes exposure shows increasing CL over time. (Bottom) 8 hour exposure shows 
increasing localization of radiolabeled oleic acid in PG over time. 
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synthesized headgroups. Studies in eukaryotes show that CL has a fatty acyl composition 
enriched in unsaturated fatty acids and that transacylases are responsible for shuttling 
fatty acids between CL and other glycerolipids (23). 
To conduct this experiment more convincingly and address my hypothesis, two-
dimensional TLC should be used to clearly separate and identify the major phospholipid 
species in E. faecalis that could contain the radiolabeled fatty acid. If we confirm that 
radiolabeled signal first appears in CL then transitions to PG, we can conduct additional 
experiments. The primary experimental concern is how to identify whether or not the 
kinetics of fatty acid incorporation facilitate inclusion of the fatty acid into phospholipid 
synthesis by one minute (T1 – Figure 5.2) or if the fatty acid is directly added to CL. If we 
indeed observe an initial increase of radiolabeled fatty acid in CL and then a subsequent 
transition into PG after 2-D TLC, we can generate conditional gene deletion strains that 
prevent incorporation of exogenous fatty acid into phospholipid synthesis. Work with 
Bacillus subtilis has demonstrated genes for PlsX, PlsY, and PlsC are essential (24). 
However, to overcome this, Paoletti et al leveraged an inducible promoter system that 
permitted the study of these genes. This study showed that removal of inducer led to plsX 
inhibition and the subsequent loss of both fatty acid and phospholipid synthesis. 
Generating an inducible system of plsX in E. faecalis, will allow us to detect if radiolabeled 
fatty acids require fatty acid/phospholipid synthesis or if radiolabeled fatty acids can be 
loaded directly onto CL. Depending on the outcome of this experiment, we can begin to 
analyze the genome of E. faecalis for proteins that could have putative acyl chain 
remodeling activity (22). 
 
Final thoughts 
 From a physiological perspective, it seems reasonable to think that E. faecalis should 
be able to use the materials inside of a host given that they have been living inside of 
animals since animals underwent terrestrialization about 425 million years ago (25). 
Furthermore, the ability of enterococci to survive harsh environments, both in host niches 
and environmental niches, is a testament to its many years of success as a bacterium 
and perhaps more importantly, why it is a significant hospital pathogen. However, what is 
enlightening is the result of membrane stress tolerance after incorporating host fatty 
142 
 
acids. Recent studies assessing proper dosage with daptomycin in order to treat 
vancomycin resistant enterococci (VRE) have reported issues in treatment outcome (26). 
This is perhaps because bacterial sensitivity to drugs is often tested in conditions that do 
not consider the host environment. As illustrated in this dissertation work, growth in the 
presence of exogenous fatty acids from the host environment improves tolerance to 
daptomycin. Although the details regarding failure of dosing have not been fully 
elucidated, it is clear that basic MICs and drug susceptibility measurements of clinical 
isolates are not performed in the presence of host fluids which clearly can protect against 
daptomycin (27). The work conducted in this dissertation may help shine a light on how 
host fatty acids can improve tolerance to membrane damaging agents, provide evidence 
that the host must be considered when testing drug sensitivity, and expands on why 
Enterococcus faecalis is able to survive so well in both clinical and homeostatic 
conditions.  
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